---
title: "Emcitate (tiratricol) in MCT8 deficiency: Clinical evidence"
description: "Formulary evidence on Emcitate (tiratricol) in MCT8 deficiency: Clinical evidence. Covers Triac trial I, ReTRIACt, Triac trial II, EMC cohort study, EMC survival study, Pediatric TRIAC case series, and 3 further headings. 234 evidence topics quoted from 25 sources."
canonical: "https://www.evicenter.com/drugs/emcitate--mct8-deficiency/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Emcitate (tiratricol) in MCT8 deficiency: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Triac Trial I

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Stated aim of the trial

> “We therefore aimed to evaluate the effectiveness and safety of Triac treatment for peripheral thyrotoxicosis in paediatric and adult patients with MCT8 deficiency. In view of the wide spectrum of patient age in our study, neurocognitive changes were assessed in an exploratory way only.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.1-2"></a>

###### Study hypothesis

> “Therefore, we hypothesised that Triac treatment could effectively reduce serum T3 concentrations, thereby improving the negative clinical sequelae of chronic tissue thyrotoxicosis in patients with MCT8 deficiency. Triac might also offer beneficial effects on neurodevelopment if treatment is commenced early in life.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study sites

> “We enrolled patients at 11 sites (ten hospitals and one outpatient facility) in eight countries in Europe (Belgium, Czech Republic, France, Germany, Italy, the Netherlands, Romania, and the UK) and one site in South Africa (appendix p 3).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.2-2"></a>

###### Screening period

> “Between Oct 15, 2014, and June 1, 2017, we screened 50 patients for eligibility for the trial, all of whom were eligible.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Investigator-initiated, open-label, single-arm, phase 2 design

> “In this investigator-initiated, multicentre, open-label, single-arm, phase 2, pragmatic trial, we investigated the effectiveness and safety of Triac in male patients with MCT8 deficiency.”
> “All patients were assigned to receive Triac for 12 months. The trial was originally intended to be a national study in the Netherlands, but it was amended to allow additional enrolment of patients in other countries.”
> “An independent data safety monitoring board monitored patient safety.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.3-2"></a>

###### Treatment extension period

> “To ascertain long-term effectiveness and safety, the patients enrolled in the Netherlands could enter an open-label treatment extension period, the endpoint of which was defined as the completion date of the last patient in other countries.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.3-3"></a>

###### Prescribing information: Study 2 design

> “Study 2 (NCT02060474) was an open-label, single-arm, multicenter study of 12 months duration that enrolled 46 male patients with MCT8 deficiency”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.1.3-4"></a>

###### German benefit assessment: study description

> “The TRIAC I study is a single-arm, open-label, multicentre phase IIb study to evaluate the safety and efficacy of tiratricol in patients with MCT8 deficiency over 12 months.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria

> “Patients with MCT8 deficiency (confirmed by the presence of a mutation in the SLC16A2 gene) were eligible to participate, irrespective of their age and comorbidities. Patients were either known to the investigators through direct care or were enrolled in the trial after their doctors or parents became aware of the trial through its ClinicalTrials.gov registration.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria

> “Exclusion criteria were major illness or major surgery within the past 4 weeks, enrolment in other randomised controlled trials, allergy to components in Triac tablets, and the presence of any contraindications to Triac treatment (appendix p 13).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.4-3"></a>

###### Withdrawal criteria

> “Patients could be withdrawn from the trial at the request of the parents or guardians, if continued participation was considered to be harmful to participants’ health by the investigators because of dose-limiting toxicities, or because of non-adherence to the trial protocol, premature termination of the trial, or loss to follow-up (appendix p 13).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.4-4"></a>

###### German benefit assessment: eligible sex, age, and genotype

> “Male subjects of any age who had a clinically relevant mutation in the MCT8 gene (SLC16A2) at screening could participate in the study.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Washout of prior thyroid medication

> “All participants discontinued treatment with antithyroid drugs, levothyroxine, or both (if applicable) before commencing treatment with the study drug. After a washout period of at least 4 weeks, baseline measurements were recorded.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.5-2"></a>

###### Dose-escalation protocol and serum total T3 target

> “We treated all patients with Triac (Téatrois tablets [350 µg], taken orally; Rare Thyroid Therapeutics, Stockholm, Sweden) with individualised dose-escalation that followed a predefined dose-escalation protocol: after the initial dose of 350 µg Triac (one tablet) once per day was given and no predefined dose-limiting toxic effects were identified, the daily dose was increased progressively in 350 µg increments (one tablet) with no maximum dose defined, with a goal of attaining serum total T3 concentrations within the target range of 1·4–2·5 nmol/L.”
> “The maintenance Triac dose was continued for the rest of the study period (appendix p 4), but it could be further adjusted according to the dose-escalation protocol if T3 concentrations were outside the target range during control visits (appendix p 4).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.5-3"></a>

###### Dose required to reach the target range

> “The median time to achieve serum T3 concentrations within the target range was 2·5 months (IQR 1·5–3·7), which required a mean daily Triac dose of 38·3 µg/kg of bodyweight (SD 15·3; range 6·4–84·3), administered as a median of three doses per day (IQR 2–3; appendix p 6).”
> “The median daily Triac dose remained stable after the dose-escalation phase, although seven (16%) of 45 patients required further dose adjustments to maintain T3 concentrations within the target range (appendix p 6). The median daily Triac dose during the final study visit, either at month 12 or at time of withdrawal, was 37·0 µg/kg bodyweight (IQR 28·9–47·2).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.5-4"></a>

###### Prescribing information: Study 2 dose titration and maintenance dose

> “The EMCITATE dose was titrated in 350 mcg daily (175 mcg daily for participants < 10 kg) increments every 2 weeks to achieve serum total T3 levels within the normal range for adults of 91 ng/dL to 163 ng/dL.”
> “The mean maintenance dose of EMCITATE was 741 mcg.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Serum T3 Concentration as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary and co-primary endpoints

> “The prespecified main primary endpoint was the change in the serum T3 concentrations between baseline and month 12. The prespecified co-primary endpoints were the change in serum TSH, free and total T4, and total reverse T3 concentrations between baseline and month 12.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.6.1-2"></a>

###### Rationale stated by the investigators: chronic tissue thyrotoxicosis

> “The endocrine hallmark of MCT8 deficiency is increased serum T3 concentrations, reduced free T4, and normal thyroid-stimulating hormone (TSH) concentrations.”
> “This chronic tissue thyrotoxicosis in patients with MCT8 deficiency leads to tachycardia, muscle wasting, hypermetabolism, and progressive reduction in bodyweight for age, causing substantial morbidity and mortality”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.6.1-3"></a>

###### German benefit assessment: clinical relevance of serum T3

> “In the present therapeutic indication, the serum thyroid hormone T3 concentration is a clinically relevant laboratory parameter which is used for diagnosis and therapy management. Normalisation of serum values is an important therapeutic goal in peripheral thyrotoxicosis. No valid data could however be identified to show what effect a specific change in T3 concentration has on patient-individual symptomatology. The endpoint is therefore only considered in addition.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Secondary endpoints

> “The prespecified secondary endpoints were the change between baseline and month 12 in bodyweight (expressed as bodyweight-for-age Z score, to account for natural development in children); mean heart rate, measured by 24 h ambulatory cardiac monitoring, and resting heart rate, measured by electrocardiography, both in bpm; blood pressure (in mm Hg and percentiles, based on reference ranges in healthy people;”
> “mean of two measurements); and established biochemical parameters that reflect thyroid hormone activity in the liver (sex hormone-binding globulin and total cholesterol) and muscle (creatine kinase). Bodyweight was assessed instead of BMI, because accurate height measurements can be hampered by scoliosis and contractures.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.6.1-5"></a>

###### Safety assessments, post-hoc endpoints, and endpoints not reported

> “The prespecified assessments were the documentation of adverse events; echocardiography and 24-h monitoring of heart rhythm; bone mineral density measurement; and biochemical evaluations, including renal and liver function tests and bone turnover markers (appendix).”
> “Post hoc, we also assessed the change in all available primary and secondary endpoints between baseline and the end of the treatment extension period in the participants treated for this time.”
> “Although the measurement of energy expenditure (secondary endpoint) and hair cortisol concentrations (exploratory endpoint) were prespecified endpoints, their acquisition was compromised by technical difficulties and are, therefore, not reported.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Sample size calculation

> “We did a power calculation based on a one-sample t test to estimate the difference in serum T3 concentrations after 12 months of treatment, by use of a mean serum T3 concentration of 4·3 nmol/L (SD 1·2), which we derived from a historical group of 31 patients with MCT8 deficiency (unpublished data). With ten patients we would have 80% power (at a significance level of 0·05) to detect a mean decrease in serum T3 concentrations from 4·3 nmol/L to 3·3 nmol/L.”
> “After approval by all relevant ethical committees, we recruited additional patients to ascertain uniform documentation of the effects of Triac in this rare disorder and to provide more meaningful data on secondary outcomes and safety measures.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.7.1-2"></a>

###### Screened, enrolled, and analyzed populations

| Population | Participants |
| --- | --- |
| Screened and eligible | “50” |
| Declined participation | “four (8%)” |
| Enrolled | “46 (92%)” |
| Primary endpoint analysis | “45 (98%)” |
| Completed the 12-month intervention period; secondary and exploratory endpoint analyses | “40 (87%)” |
| Treatment extension period | “Ten (22%)” |

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Full analysis set, completer set, and safety population

> “Analyses of the prespecified primary endpoints were based on the full analysis dataset, which included all patients who received at least one dose of Triac and who had at least one control visit after the baseline assessment (appendix p 4). As such, patients who withdrew were included in the analyses, with their last available measurement used. The main analyses of the prespecified secondary endpoints were done in all patients who completed 12 months of treatment.”
> “Analyses of safety endpoints were done in the safety population, which included all patients exposed to at least one dose of the study drug.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.7.2-2"></a>

###### Statistical methods

> “For all prespecified primary and secondary endpoints, p values and 95% CIs were calculated for the mean change between baseline and month 12 by use of paired Student’s t tests. Serum TSH and creatine kinase concentrations were first log-transformed to normalise the distribution. For all prespecified exploratory and safety measures, 95% CIs were calculated for the mean change between baseline and 12 months of Triac treatment.”
> “Two-sided p values of less than 0·05 were considered to denote statistical significance.”
> “CIs for exploratory measures have not been adjusted for multiplicity and these data should not be used to infer definitive treatment effects.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.7.2-3"></a>

###### Missing data

> “With the assumption that omission of data occurred randomly, and given the broad age range of the participants and small group size, pairwise deletion was used to adjust for missing data that were only captured at baseline and 12 months; for missing data that were captured throughout the study, the last available measurement was used.”
> “If 12-month measurements were not available, the last available observation in the same patient was used (<3% of included datapoints).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.7.2-4"></a>

###### Caregiver-reported outcomes: post-hoc analysis methods

> “To study the effect of Triac on patient-centered outcome measures in the Triac Trial I.”
> “We performed post-hoc analyses on caregiver-reported patient-centered outcome measures from the multicentre, phase 2, single-arm, open-label Triac Trial I. In this trial, 40 patients with MCT8 deficiency completed 1 year of Triac treatment. At baseline, during clinical visits and at the end of the study, semi-structured interviews were held with caregivers on complex needs and daily care challenges, including motor skills, sleep problems, seizure frequency and most prominent changes. Moreover, parents were asked to report perceived changes in (thyrotoxic) symptoms such as increased perspiration and hyposialia.”

Source: [Freund et al. (2024b)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBApuzKXgUtI5BZ-DdOMMKdRwzqjq-XL7Dq3vHEdWn0Na0)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Enrollment and withdrawals

> “Between Oct 15, 2014, and June 1, 2017, we screened 50 patients, all of whom were eligible. Of these patients, four (8%) patients decided not to participate because of travel commitments.”
> “Of these 50 patients, four declined to participate; 46 patients were therefore enrolled and assigned to receive Triac (appendix p 5), but one (2%) patient was withdrawn before the first control visit because of non-compliance to study procedures. This patient was included in safety analyses, but not primary efficacy analyses.”
> “Five of these patients did not complete the study intervention: two were withdrawn due to parental choice (one because of travel time to the study centre, one because of severe comorbidity [severe epileptic seizures and hydrocephalus]), one was lost to follow-up, one developed Graves’ disease, and one patient died from sepsis. 40 (87%) patients completed the 12-month intervention period and thus were included in the analyses of secondary and exploratory endpoints. Ten (22%) patients who completed the follow-up were also included in the long-term (median 40·4 months, IQR 38·1–41·3) treatment extension period (appendix p 5).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Age, serum T3, bodyweight, and developmental status at baseline

> “At baseline, the median age of the overall study population (n=46) was 7·1 years (range 0·8–66·8) and the mean serum T3 concentration was 4·91 nmol/L (SD 1·57), which was more than 1·6-times the upper limit of the normal range for age (table 1). The mean weight-for-age Z score was –2·84 (1·88) and 30 (65%) of the 46 enrolled patients were underweight (Z score less than –2). All patients had severe intellectual and motor disability: 41 (89%) of 46 patients were wheelchair-bound and had not reached early developmental milestones such as independent sitting.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.2-2"></a>

###### Baseline characteristics table

| Characteristic | Triac, n = 46 |
| --- | --- |
| Age younger than 4 years, n (%) | “11 (24%)” |
| Age 4 to 10 years, n (%) | “19 (41%)” |
| Age 11 to 18 years, n (%) | “11 (24%)” |
| Adults older than 18 years, n (%) | “5 (11%)” |
| Male, n (%) | “46 (100%)” |
| White race, n (%) | “44 (96%)” |
| No or poor head control, n (%) | “32 (70%)” |
| Able to sit independently, n (%) | “5 (11%)” |
| Uses a feeding tube, n (%) | “20 (43%)” |
| Resting tachycardia (above the 90th percentile for age) | “19 (43%) of 44 patients with data available” |
| Systolic hypertension | “12 (34%) of 35 patients with baseline blood pressure measurements” |

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.2-3"></a>

###### Prescribing information: Study 2 age and race

> “The median age of participants was 7.1 years (range: 10 months to 66.8 years). The majority (96%) of participants were White, 2% were Asian and 2% were other races.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### German benefit assessment: age distribution

> “A total of 46 patients aged between 10 months and 67 years (mean 10.4 years) were enrolled. Only 5 study participants were under 2 years of age and no patient was treated in the postnatal period.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: serum T3 concentration at month 12

> “In the 45 patients assessed for the primary endpoint, serum T3 concentrations had significantly decreased by month 12 (median 13·1 months [IQR 12·4–13·9]), with a mean decrease of 3·15 nmol/L (95% CI 2·68–3·62; p<0·0001; figure 1; table 2), equivalent to 61% (56–66) from baseline.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-2"></a>

###### Co-primary endpoints: TSH, free and total T4, and reverse T3

> “We also identified significant reductions in serum free T4 concentrations (mean decrease 6·1 pmol/L, 5·4–6·8; p<0·0001) and serum TSH concentrations (mean decrease 1·89 mU/L, 1·39–2·39; p<0·0001). Additionally, serum total T4 concentrations decreased by 31·6 nmol/L (28·0–35·2; p<0·0001) and reverse T3 by 0·08 nmol/L (0·05–0·10; p<0·0001; (appendix p 7).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-3"></a>

###### Primary and secondary outcomes, baseline to month 12

| Outcome | Baseline, mean (SD) | Month 12, mean (SD) | Mean change (95% CI) | p value |
| --- | --- | --- | --- | --- |
| T3, nmol/L (n = 45) | “4·97 (1·55)” | “1·82 (0·69)” | “–3·15 (–3·62 to –2·68)” | “<0·0001” |
| TSH, mU/L (n = 45) | “2·91 (1·68)” | “1·02 (1·14)” | “–1·89 (–2·39 to –1·39)” | “<0·0001” |
| Free T4, pmol/L (n = 45) | “9·5 (2·5)” | “3·4 (1·6)” | “–6·1 (–6·8 to –5·4)” | “<0·0001” |
| Total T4, nmol/L (n = 45) | “56·0 (13·0)” | “24·4 (9·4)” | “–31·6 (–35·2 to –28·0)” | “<0·0001” |
| Reverse T3, nmol/L (n = 45) | “0·12 (0·10)” | “0·04 (0·04)” | “–0·08 (–0·10 to –0·05)” | “<0·0001” |
| Weight-for-age Z score (n = 40) | “–2·98 (1·93)” | “–2·71 (1·79)” | “0·27 (0·03 to 0·50)” | “0·025” |
| Resting heart rate, bpm (n = 34) | “112 (23)” | “104 (17)” | “–9 (–16 to –2)” | “0·010” |
| Mean heart rate over 24 h, bpm (n = 31) | “102 (14)” | “97 (9)” | “–5 (–9 to –1)” | “0·012” |
| Systolic blood pressure, mm Hg (n = 32) | “108 (8)” | “102 (10)” | “–5 (–9 to –1)” | “0·0086” |
| Systolic blood pressure, percentile (n = 32) | “78 (24)” | “61 (29)” | “–18 (–29 to –6)” | “0·0037” |
| Diastolic blood pressure, mm Hg (n = 32) | “64 (9)” | “62 (9)” | “–2 (–6 to –2)” | “0·35” |
| Sex hormone-binding globulin, nmol/L (n = 39) | “212 (91)” | “178 (76)” | “–35 (–55 to –15)” | “0·0013” |
| Total cholesterol, mmol/L (n = 40) | “3·2 (0·7)” | “3·4 (0·7)” | “0·2 (0·0 to 0·3)” | “0·056” |
| Creatine kinase, U/L (n = 40) | “108 (90)” | “161 (117)” | “53 (27 to 78)” | “<0·0001” |

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-4"></a>

###### Attainment of the serum T3 target range

> “In the post-hoc analyses to assess only the patients who completed 12 months of treatment, we found that 34 (85%) of 40 patients had attained serum T3 concentrations within the target range by month 12, and the remaining patients had concentrations just above the target range, but that their T3 measurements had been within the target range during the previous study assessment visit.”
> “By month 4, 35 (78%) of 45 patients had attained T3 concentrations within the target range (appendix p 6).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-5"></a>

###### Secondary endpoints: bodyweight, heart rate, blood pressure, and tissue markers

> “We assessed the secondary endpoints in the 40 patients who completed the 12-month treatment. We identified a significant increase in weight-for-age Z score at month 12 (0·27 SDs, 95% CI 0·03–0·50; p=0·0253; figure 1; table 2; appendix p 8), equating to a mean increase in body weight of 2·7 kg (1·9–3·5; p<0·0001); by contrast, in untreated patients, the bodyweight-for-age Z score has been shown to progressively reduce over time (appendix p 8).”
> “Between baseline and month 12, resting heart rate, as measured by electrocardiography, decreased by 9 bpm (95% CI 2–16; p=0·010), and mean heart rate, as measured by 24-h cardiac monitoring, decreased by 5 bpm (1–9; p=0·012; appendix p 9). Mean systolic blood pressure decreased over the 12-month study from the 78th percentile to the 61th percentile, equating to a change of 18 percentile points (95% CI 6–29; p=0·0037; table 2). The proportion of patients with systolic hypertension decreased from 34% (n=12/35) at baseline to 9% (n=3/32 at month 12).”
> “The serum concentrations of sex hormone-binding globulin decreased by 35 nmol/L (15–55; p=0·0013). However, mean serum total cholesterol concentration did not significantly change between baseline and month 12 (difference 0·2, 95% CI 0·0–0·3; p=0·056). Finally, serum creatine kinase concentrations increased by 53 U/L (27–78; p<0·0001) by month 12 (table 2; appendix p 10).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-6"></a>

###### Exploratory endpoint: gross motor function

> “The greatest increase in gross motor function was in patients in whom Triac treatment was started before age 4 years (figure 1).”
> “From the seven patients with a completely inactivating mutation who had started with Triac treatment before the age of 4 years, two reached this developmental stage by month 12 of treatment.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-7"></a>

###### Post-hoc treatment extension period

> “Post-hoc analyses of the treatment extension endpoints included ten patients. During the long-term treatment extension period, the reductions in T3 concentrations persisted in all patients (figure 2; appendix p 21) and reductions in TSH and free T4 concentrations were maintained (appendix pp 11,21).”
> “The improvement in bodyweight-for-age Z score was maintained, with a mean increase of 0·52 SDs (95% CI 0·02–1·02) at month 12 and 0·62 (0·12–1·12) at month 32, relative to baseline. Bodyweight (figure 2), height, and BMI trajectories improved relative to their anticipated natural course in seven (88%) of the eight paediatric patients (appendix p 12).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.3-8"></a>

###### Prescribing information: Study 2 serum total T3, baseline to month 12

| Variable | N | Baseline, mean (SD) | Month 12, mean (SD) | Difference, mean [95% CI] |
| --- | --- | --- | --- | --- |
| T3, ng/dL | “45” | “323.4 (100.8)” | “118.3 (44.6)” | “-205.2 [-235.7; -174.6]” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

> “Data were imputed as Last Observation Carried Forward for patients who discontinued treatment prior to Month 12 visit.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.1.8.3-9"></a>

###### Prescribing information: Study 2 secondary endpoints at month 12

> “At Month 12, there was a mean (95% confidence interval) change of: -4.1 (-8.1, -0.1) mmHg from a baseline of 107.1 mmHg in systolic blood pressure (N = 35 participants); -8.9 (-15.6, -2.3) beats per minute (bpm) from a baseline of 112.4 bpm in heart rate (N = 34 participants), 0.22 (-0.01, 0.45) from a baseline of -2.85 in body weight-for-age Z-score (N = 45 participants) and 0.51 (0.25, 0.76) from a baseline of 0.46 in body weight-for-age Z-score in an untreated MCT8 patient population (N = 36 participants).”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.1.8.3-10"></a>

###### German benefit assessment: anthropometric results against a healthy reference population

> “The data on body height and body weight in relation to the healthy reference population (WHO reference population) were used for the present benefit assessment. However, it should be noted that the present analyses also include data from adults who have already completed their physical development. In the TRIAC I study, there was no significant change in the z-score compared to baseline for body weight as well as body height at the end of the study.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="topic-3.1.1.8.3-11"></a>

###### Regulatory assessment of neurodevelopmental delay

> “Emcitate did not improve neurodevelopmental delay.”

Source: [European Medicines Agency (2024)](https://www.ema.europa.eu/en/news/first-treatment-peripheral-thyrotoxicosis-patients-allan-herndon-dudley-syndrome)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Prospectively collected quality-of-life and neurocognitive endpoints

> “The patient-reported endpoints of Gross Motor Function Measure-88 (GMFM-88), Bayley Scales of Infant and Toddler Development - Third Edition (BSID-III) and Vineland Adaptive Behaviour Scales - Second Edition (VABS-II) on neurocognitive development collected in the TRIAC I study were not used for the benefit assessment due to the low return rates (< 70%).”
> “No endpoints on quality of life were collected in the TRIAC I study.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="topic-3.1.1.8.4-2"></a>

###### Caregiver-reported outcomes from Triac Trial I: results

> “The most prominent changes upon Triac treatment reported by caregivers were improved interaction (22/39), greater alertness (19/39), improved motor skills (12/39), improved head control (7/39), and improved sleep (8/39). For one patient, also negative changes were reported, specifically increased constipation and higher unsettledness.”
> “Compared to the baseline visit, excessive perspiration was much less reported (48,6% vs. 8,1%) and less hyposialia (30,6% vs 22,2%) was observed by the caregivers at the end study visit. Seizures and continence were reportedly unchanged. All parents (40/40) preferred to continue Triac treatment.”

Source: [Freund et al. (2024b)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBApuzKXgUtI5BZ-DdOMMKdRwzqjq-XL7Dq3vHEdWn0Na0)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Adverse events and treatment-related adverse events

> “All 46 patients who received at least one dose of Triac were included in drug safety analyses. 43 (93%) patients had at least one adverse event (table 3; appendix p 22). Triac treatment was continued during hospital admission in all but one patient. All seven adverse events that were suspected to be related to Triac treatment, which occurred in six (13%) patients, were mild: three patients had a transient increase in perspiration and three patients reported transient irritability. The onset of these events coincided with the start of Triac treatment or modification in Triac dose and resolved spontaneously after a few days. No patients required a dose reduction or discontinued participation because of drug-related toxicity.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.5-2"></a>

###### Serious adverse events and death

> “26 serious adverse events that were considered unrelated to treatment occurred in 18 (39%) patients (mostly hospital admissions because of infections).”
> “Most serious adverse events were intermittent infections that were treated with antibiotics and supportive care. All serious adverse events were considered to be secondary to MCT8 deficiency and, thus, unrelated to Triac (table 3). In three patients with preexisting seizures, an increase in seizure frequency was reported.”
> “One patient died from pulmonary sepsis leading to multiorgan failure; post-mortem examination confirmed the clinical diagnosis, and other causes were excluded.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.5-3"></a>

###### Adverse events in more than 10% of participants, serious events, and severity

| Adverse event | Participants with at least one event, n (%), N = 46 | Number of events |
| --- | --- | --- |
| Total adverse events | “43 (93%)” | “150” |
| Gastroenteritis | “11 (24%)” | “12” |
| Nasopharyngitis | “11 (24%)” | “14” |
| Influenza or influenza-like illness | “9 (20%)” | “12” |
| Upper-respiratory-tract infection | “9 (20%)” | “9” |
| Bronchitis | “6 (13%)” | “6” |
| Diarrhoea | “5 (11%)” | “5” |
| Vomiting | “5 (11%)” | “5” |
| Otitis media | “5 (11%)” | “5” |
| Serious adverse events | “18 (39%)” | “26” |
| Fatal adverse events | “1 (2%)” | “1” |
| Adverse events leading to premature treatment discontinuation (autoimmune thyroid disorder) | “1 (2%)” | “1” |
| Severe adverse events | “4 (9%)” | “4” |
| Moderate adverse events | “4 (9%)” | “5” |
| Mild adverse events | “40 (87%)” | “141” |
| Probable relation to the study drug | “6 (13%)” | “7” |

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.5-4"></a>

###### Cardiac, bone, and liver safety measures

> “Of the safety measures prespecified in the protocol (appendix p 14–16), no clinically relevant changes in cardiac structure or function were identified.”
> “Serum β-carboxy-terminal collagen crosslinks increased by 0·14 µg/L (95% CI 0·03–0·25) and bone-specific alkaline phosphatase concentrations increased by 8·4 µg/L (2·7–14·1), without affecting bone mineral density (appendix p 23), consistent with the physiological increase of bone turnover markers in paediatric patients during development.”
> “25 (54%) of 46 patients showed mildly increased serum concentrations of alanine aminotransferase, aspartate aminotransferase, or γ-glutamyl transferase at baseline, which was attributed to the concomitant use of hepatotoxic medications, and these concentrations did not increase further during the study. Two (4%) patients showed an increase in aminotransferase concentrations that were attributed to commencement or dose adjustment of anticonvulsant drugs with known hepatotoxicity (levetiracetam and lamotrigine).”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.8.5-5"></a>

###### Prescribing information: Study 2 adverse reactions

| Adverse reaction | Study 2, EMCITATE, N = 46, n (%) |
| --- | --- |
| Diarrhea | “6 (13)” |
| Vomiting | “5 (11)” |
| Rash | “4 (9)” |
| Hyperhidrosis | “3 (7)” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Prescribing information: Study 2 transient increases in heart rate and systolic blood pressure during titration

> “In Study 2, transient increases in heart rate and systolic blood pressure”
> “were observed in 35% and 26% of participants, respectively, during the titration period. In addition, 30% of participants experienced at least one adverse reaction potentially related to thyrotoxicosis during the trial (diarrhea, hyperhidrosis, irritability, insomnia, nightmares), with most of these adverse reactions occurring during the titration period”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.1.8.5-7"></a>

###### German benefit assessment: adverse event reporting

> “Adverse events (AEs) occurred in more than 90% of patients (only presented additionally). Serious AEs (SAEs) were documented in almost 40% of the study participants and 2% thereof discontinued the study due to AEs. For the endpoint "severe AEs", there were uncertainties regarding the operationalisation of the severity grading, which could also not be clarified as part of the written statements made by the pharmaceutical company. Based on the information available, it cannot be ruled out that severe AEs were under-assessed.”
> “Overall, interpretation and assessment of the data on side effects are not possible due to the missing control group.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

Triac Trial I was an open-label, single-arm, phase 2 trial in which 46 participants were enrolled, 45 were included in the primary analysis, and 40 completed 12 months of treatment. The investigators state that the absence of a control group and the open-label design do not allow causality to be proven, that the sample size did not allow control for factors other than the intervention, that few adults were enrolled, and that missing measurements and withdrawals may have caused selection bias. The trial was not designed to assess neurodevelopment. The G-BA did not identify validated evidence linking a given change in serum T3 to individual symptoms, found no significant change in bodyweight or height z-scores against a WHO reference population, did not use the neurocognitive endpoints because fewer than 70% of assessments were returned, noted that no quality-of-life endpoints were collected, and could not rule out under-assessment of severe adverse events. The caregiver-reported outcomes come from a post-hoc analysis of an open-label trial.

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/); [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf); [Freund et al. (2024b)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBApuzKXgUtI5BZ-DdOMMKdRwzqjq-XL7Dq3vHEdWn0Na0)

<a id="topic-3.1.1.9-2"></a>

###### Limitations stated by the investigators

> “Inherent to studies in such a heterogeneous population, the effect size of outcomes varied within the study cohort, suggesting inter-individual variation in degree of benefit between patients. The small sample size did not allow identification or statistical control for factors other than the intervention that might modulate treatment effects. Another limitation was the small number of adult patients enrolled in the study, as a consequence of high mortality during childhood. Moreover, the low physical and cognitive abilities of the participants, a feature that is inherent to the disorder, precluded recording some study parameters in all patients. Together with study withdrawals, this issue might have, unavoidably, caused selection bias in the data used for statistical analyses.”
> “Although our study design, including the absence of a control group and open-label design, does not enable us to prove causality, the observed unidirectional changes in serum T3 concentrations can likely be attributed to Triac treatment, given the substantial evidence from preclinical and clinical studies on the effects of Triac”
> “Our trial was not designed to detect whether Triac also modulates neurodevelopment in human MCT8 deficiency, since the study did not include specific neurodevelopmental outcomes and enrolled patients of all ages. Therefore, most patients studied would have passed the small window of opportunity to modulate brain development.”

Source: [Groeneweg et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31377265/)

<a id="topic-3.1.1.9-3"></a>

###### German benefit assessment: absence of a comparator

> “However, no conclusions on the extent of the additional benefit for the mortality category could be derived due to the absence of comparator data.”
> “Overall, the available data can nevertheless only be interpreted with difficulty in terms of their significance, as no assessment is possible on the basis of the non-comparator data in comparison to the natural course of the disease in the present patient population.”
> “Overall, quantification of the extent of the additional benefit on the basis of the available study results is not possible due to the lack of comparison.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 ReTRIACt

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Objective: effect of withdrawal on serum total T3

> “Objective: To assess the effects of withdrawal of tiratricol vs continued treatment on serum total T3 concentrations.”

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="topic-3.1.2.1-2"></a>

###### Planned purpose of the study at enrollment

> “After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications.”

Source: [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### International multicenter study

> “The efficacy of EMCITATE in patients with MCT8 deficiency was evaluated in an international, multicenter study (Study 1; NCT05579327) that consisted of three study periods as follows:”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.2-2"></a>

###### Study closure after the pre-NDA meeting

> “As recommended by the FDA, the Statistical Analysis Plan (SAP) for the ReTRIACt trial will be revised and the study will be closed.”
> “Topline results will be communicated during the fourth quarter of 2025.”
> “Data accrued to date will be included in the NDA.”

Source: [Egetis Therapeutics rolling NDA review announcement (2025)](https://www.egetis.com/news/egetis-granted-a-rolling-nda-review-by-fda-for-emcitate-tiratricol-based-on-currently-available-clinical-data/)

Additional sources: [ClinicalTrials.gov NCT05579327](https://clinicaltrials.gov/study/NCT05579327)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Randomized withdrawal design

> “The ReTRIACt study (clinicaltrials.gov identifier NCT05579327) is a double-blind, multicenter, placebo-controlled, randomized, withdrawal study in patients with MCT8 deficiency.”

Source: [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/)

<a id="topic-3.1.2.3-2"></a>

###### Phase and randomization ratio

> “Methods: ReTRIACt (NCT05579327) was a phase 3, multicenter, double-blind, randomized, placebo-controlled study.”
> “Male subjects ≥4 years of age on stable maintenance treatment with tiratricol were randomized 1:1 to receive placebo or tiratricol for 30 days (randomized treatment period, RTP) or until reaching the rescue criterion (serum total T3 above upper limit of normal, measured by LCMS/MS).”

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="topic-3.1.2.3-3"></a>

###### Prescribing information: three study periods

> “Study 1 (NCT05579327) was a 3-period, multicenter study with an up to 16-week, open-label, titration period followed by a 30-day randomized double-blind, placebo-controlled withdrawal period, then a 6-week open-label treatment period.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

| Study period | Description |
| --- | --- |
| Screening period | “6-week run-in period for participants already treated with EMCITATE (Cohort A) and a 16-week dose-titration period for participants newly started on EMCITATE (Cohort B).” |
| Randomized treatment period | “30-day double-blind, placebo-controlled, randomized withdrawal period, which provided data for the primary efficacy endpoints.” |
| Follow-up period | “6-week open-label treatment period.” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Age, sex, and stable maintenance treatment

> “Males 4 years of age and above who demonstrated stable maintenance treatment with tiratricol, were randomized to continue tiratricol or receive placebo for 30 days or until reaching the rescue criterion (serum total triiodothyronine [T3] > upper limit of normal [ULN]).”

Source: [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/)

<a id="topic-3.1.2.4-2"></a>

###### Prescribing information: stable dose criterion for randomization

> “The stable dose criterion was defined as at least 4 weeks of treatment with a fixed daily dose of EMCITATE and at least 2 consecutive serum total T3 results within the target range (between 80% of the lower limit of normal and no higher than the 75th percentile of the normal range).”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Prescribing information: screening-period titration

> “Twenty participants with MCT8 deficiency were enrolled during the Screening Period: 10 participants in Cohort A, who were already receiving EMCITATE treatment, and 10 participants in Cohort B, who were started on EMCITATE 350 mcg daily.”
> “The EMCITATE dose was titrated by 350 mcg daily every 2 weeks based on serum total T3 to achieve the stable dose criterion.”
> “The mean duration of treatment with EMCITATE during this period was 86 days in Cohort A and 77 days in Cohort B.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.5-2"></a>

###### Prescribing information: randomized treatment and follow-up periods

> “Serum total T3 was measured weekly during this period.”
> “If the rescue criterion was met, the subject stopped the blinded study treatment and re-initiated EMCITATE at the pre-randomization dose.”
> “After completion of the RTP, 14 participants entered a 6-week follow-up period and received EMCITATE at the stable maintenance dose received prior to randomization.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Serum T3 Rate of Change as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoints

> “Primary endpoints were the rate of change in serum total T3 and the proportion of subjects requiring rescue during the RTP.”

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="topic-3.1.2.6.1-2"></a>

###### Addition of the T3 rate-of-change endpoint after FDA comments

> “Furthermore, based on comments from the FDA, the Statistical Analysis Plan (SAP) of the ReTRIACt study was revised, and the study was closed.”
> “A Primary Endpoint 1 (PE1), evaluating rate of change in serum total T3 during the double-blind Randomized Treatment Period, was added to the previously described Primary Endpoint 2 (PE2), based on the T3 rescue criterion.”

Source: [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/)

<a id="topic-3.1.2.6.1-3"></a>

###### Sponsor rationale: serum T3 as the biochemical driver of disease

> “ReTRIACt study provides randomized controlled evidence of tiratricol’s pharmacodynamic effect on T3, the key biochemical driver of disease morbidity and mortality.”

Source: [Egetis Therapeutics rolling NDA submission completion announcement (2026)](https://www.egetis.com/news/egetis-completes-the-u-s-rolling-nda-submission-for-emcitate-tiratricol-for-treatment-of-mct8-deficiency/)

<a id="topic-3.1.2.6.1-4"></a>

###### Prescribing information: primary efficacy endpoints and rescue criterion

> “The two primary efficacy endpoints were: 1) Rate of change from baseline in serum total T3 during the 30-day Randomized Treatment Period; 2) Proportion of participants who met the rescue criterion during the 30-day Randomized Treatment Period.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned number of evaluable participants

> “After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications.”

Source: [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/)

<a id="topic-3.1.2.7.1-2"></a>

###### Prescribing information: randomized population

> “Fifteen participants (8 participants from Cohort A and 7 participants from Cohort B) achieved the stable dose criterion and were randomized (1:1) to receive placebo or continue EMCITATE treatment for 30 days or until the rescue criterion, defined as the serum total T3 above the upper limit of normal (ULN), was met.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Multiplicity control and handling of a discontinuation

> “Type I Error is controlled via alpha recycling, testing PE1 first, and if PE1 is met, PE2 will then be tested.”
> “One patient randomized to tiratricol discontinued (not drug related) during the randomized treatment period, which per the SAP was imputed as rescue in PE2, leading to a 4 (placebo) versus 1 (tiratricol) comparison for PE2 (p=0.182).”

Source: [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/)

<a id="topic-3.1.2.7.2-2"></a>

###### Prescribing information: analysis set and model

| Analysis element | Quoted record |
| --- | --- |
| Analysis set for both primary endpoints | “Full Analysis Set” |
| Model for primary endpoint 1 | “Estimates from random effects model” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Prescribing information: enrollment, randomization, and follow-up

> “Twenty participants with MCT8 deficiency were enrolled during the Screening Period: 10 participants in Cohort A, who were already receiving EMCITATE treatment, and 10 participants in Cohort B, who were started on EMCITATE 350 mcg daily.”
> “After completion of the RTP, 14 participants entered a 6-week follow-up period and received EMCITATE at the stable maintenance dose received prior to randomization.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.8.1-2"></a>

###### Discontinuation during the randomized treatment period

> “One subject randomized to tiratricol discontinued during the RTP due to non-medical family reasons.”

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Prescribing information: age, sex, and race of enrolled participants

> “The median age of the 20 participants enrolled in the study was 11 years, ranging from 5 to 31 years. All subjects were male. There were 65% White, 15% Black or African Americans, 5% Asian, 5% American Indian or Alaska Native and 10% other races.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### Prescribing information: baseline serum total T3 by arm

> “The mean (SD) change from baseline to the end of the Randomized Treatment Period in total T3 levels was 64.6 (12.7) ng/dL from a baseline of 109.1 ng/dL in the placebo arm and -0.2 (12.5) ng/dL from a baseline of 100.5 ng/dL in the tiratricol arm.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Prescribing information: primary endpoint 1, total T3 rate of change

| Measure | Placebo | Tiratricol |
| --- | --- | --- |
| N | “8” | “7” |
| T3 rate of change [95% CI] | “1.6 [1.2; 2.1]” | “1.1 [0.8; 1.3]” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

| Comparison | Value |
| --- | --- |
| Ratio of T3 rate of change, placebo/tiratricol [95% CI] | “1.5 [1.0; 2.2] (p-value=0.034)” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

> “The mean (SD) change from baseline to the end of the Randomized Treatment Period in total T3 levels was 64.6 (12.7) ng/dL from a baseline of 109.1 ng/dL in the placebo arm and -0.2 (12.5) ng/dL from a baseline of 100.5 ng/dL in the tiratricol arm.”
> “The treatment difference (95% CI) in total T3 change from baseline at the end of randomized treatment period was 64.8 ng/dL (44.7, 84.8) for placebo versus tiratricol arm.”
> “After withdrawal of EMCITATE, all 8 participants randomized to placebo had an increase in serum total T3 during the randomized treatment period (range: 31.9 to 135.4 ng/dL) that was larger than what was seen in the 7 patients randomized to continue EMCITATE (range: -15.6 to 26.0 ng/dL).”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.8.3-2"></a>

###### Prescribing information: primary endpoint 2, rescue criterion

| Outcome | Tiratricol, N=7 | Placebo, N=8 |
| --- | --- | --- |
| Rescue criterion not met, n (%) | “6 (85.7)” | “4 (50.0)” |
| Rescue criterion met, n (%) | “1* (14.3)” | “4 (50.0)” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

| Comparison | Value |
| --- | --- |
| Difference in proportions, placebo minus tiratricol | “0.36” |
| 95% CI | “-0.16, 0.77” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

> “One participant who discontinued prematurely during the Randomized Treatment Period was considered to have met the rescue criterion.”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.8.3-3"></a>

###### Prescribing information: secondary heart rate and blood pressure endpoints

> “Secondary efficacy endpoints assessing mean changes in heart rate and systolic blood pressure from screening until pre-randomization and from screening until end of study showed a trend towards numerical improvements in participants in Cohort B (treatment-naïve), while heart rate and blood pressure remained stable in participants in Cohort A (previously-treated).”

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### Primary endpoints in SI units, observed-case rescue analysis, and reinitiation

> “The Primary Endpoint 1 (PE1), rate of change in serum T3 during the Randomized Treatment Period, showed a statistically significant difference between placebo and tiratricol (ratio of T3 rate of change (placebo/tiratricol): 1.494 [95% CI: 1.035; 2.155]; p=0.034).”
> “The results show a complete separation of the two groups with all 8 patients randomized to placebo having an increase in serum T3 during the randomized treatment period (range: 0.49 – 2.08 nmol/L), larger than all 7 patients randomized to continue tiratricol (range: -0.24 – 0.40 nmol/L).”
> “In the placebo group, 4 patients met the rescue criterion during the randomized treatment period compared to 0 patients randomized to tiratricol (p=0.070 on observed cases of rescue).”
> “One patient randomized to tiratricol discontinued (not drug related) during the randomized treatment period, which per the SAP was imputed as rescue in PE2, leading to a 4 (placebo) versus 1 (tiratricol) comparison for PE2 (p=0.182).”
> “All patients randomized to placebo showed an expected decrease in serum T3 levels following reinitiation of tiratricol in the follow-up period.”

Source: [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/)

<a id="topic-3.1.2.8.3-5"></a>

###### Congress report: estimated relative change in serum T3 over 30 days

| Arm | Estimated increase in serum T3 over the 30-day randomized treatment period |
| --- | --- |
| Placebo | “59%” |
| Tiratricol | “6%” |

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

> “All subjects randomized to placebo had an expected decrease in serum T3 upon reinitiation of tiratricol in the follow-up period.”
> “Conclusions: In this placebo-controlled trial of tiratricol in subjects with MCT8 deficiency, we showed that withdrawal of tiratricol results in a significant increase in serum T3.”

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Prescribing information: Study 1 adverse reactions

| Adverse reaction | Study 1, EMCITATE, N = 20, n (%) |
| --- | --- |
| Diarrhea | “0” |
| Vomiting | “2 (10)” |
| Rash | “2 (10)” |
| Hyperhidrosis | “1 (5)” |

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### Serious adverse events and death

> “Tiratricol was well-tolerated: six serious adverse events were reported in four subjects; none were considered treatment-related.”
> “There was one death due to aspiration pneumonia and resultant respiratory failure.”

Source: [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

ReTRIACt enrolled 20 participants and randomized 15 of them (eight to placebo withdrawal, seven to continued tiratricol); in 2024 the manufacturer described the planned study as including 16 evaluable participants. The study was closed at the FDA's recommendation, and the analysis plan was revised to add the T3 rate-of-change endpoint (primary endpoint 1) before that endpoint was reported. Primary endpoint 1 met its significance criterion (ratio 1.5, 95% CI 1.0 to 2.2; p=0.034). For the rescue endpoint (primary endpoint 2), the difference in proportions was 0.36 with a 95% CI of -0.16 to 0.77 (p=0.182); one discontinuation in the tiratricol group for non-medical family reasons was counted as rescue, and the observed-case comparison was 4 versus 0 (p=0.070). The randomized period lasted at most 30 days and evaluated withdrawal after stable maintenance treatment; it did not evaluate treatment initiation or long-term clinical outcomes. The prescribing information reports adverse reactions for all 20 enrolled participants and does not report them by randomized arm. The congress report lists six serious adverse events in four participants and one death from aspiration pneumonia, none considered treatment-related. Enrolled participants were aged 5 to 31 years, so the study did not include infants.

Source: [Egetis Therapeutics EMCITATE prescribing information (2026)](https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf); [Egetis Therapeutics ReTRIACt results announcement (2025)](https://www.egetis.com/news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/); [Egetis Therapeutics rolling NDA review announcement (2025)](https://www.egetis.com/news/egetis-granted-a-rolling-nda-review-by-fda-for-emcitate-tiratricol-based-on-currently-available-clinical-data/); [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/); [Freund et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119op-03-05)

<a id="heading-3.1.3"></a>

#### 3.1.3 Triac Trial II

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registry objective and hypothesis

> “This study will investigate the effect of treatment with tiratricol (also called Triac) in young boys (≤30 months) with MCT8 deficiency (also called the Allan-Herndon-Dudley syndrome (AHDS)). The hypothesis tested is that treatment with tiratricol will have a beneficial effect on the hypothyroid state in the brain as well as the hyperthyroid state in peripheral organs and tissues in these patients.”

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="topic-3.1.3.1-2"></a>

###### Regulatory description of the study aim

> “Triac Trial II is a 96-week study (Part I) designed to evaluate the effects of tiratricol on neurodevelopment in young (≤30 months of age) patients with MCT8 deficiency. In addition, the study provides data on treatment effects on serum T3, clinical aspects of thyrotoxicosis and safety data in the youngest patients, dosed with considerably higher doses than in previous clinical studies.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.1-3"></a>

###### Principal investigator: early-treatment hypothesis

> “Our research hypothesis when we designed the Triac Trial II, based on preclinical data and on exploratory outcomes we observed in Triac Trial I, was to investigate if young patients with MCT8 deficiency might have a neurocognitive benefit from tiratricol treatment, if the treatment is started early.”

Source: [Egetis Therapeutics Triac Trial II topline results announcement (2024)](https://www.egetis.com/news/egetis-announces-topline-results-of-the-phase-2-triac-trial-ii-with-emcitate-tiratricol-for-mct8-deficiency/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Registry dates and enrollment

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2020-12-07” |
| Primary completion (estimated) | “2027-07-18” |
| Study completion (estimated) | “2027-08-18” |
| Recruitment status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="topic-3.1.3.2-2"></a>

###### Registry study sites

| Country | Site |
| --- | --- |
| United States | “Oregon Health & Science University (OHSU) Doernbecher Childrens Hospital” |
| United States | “Children's Hospital of Philadelphia” |
| Czechia | “Charles University and Motol University Hospital; The department of peadiatrics of the 2nd faculty of medicine” |
| Germany | “Charité - Universitätsmedizin Berlin Institut fur experimental paediatrische endokrinologie” |
| Netherlands | “Erasmus MC” |

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="topic-3.1.3.2-3"></a>

###### Screening period

> “Results: Between Dec 3, 2020, and Jun 22, 2022, we screened 23 male patients.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase 2, open-label, multicentre, single-arm trial

> “Methods: We performed a phase II, open-label, multicentre, clinical trial (NCT02396459), which investigated the effect of Triac treatment on the motor and cognitive development of male patients with MCT8 deficiency, aged 0-30 months at baseline.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

| Design field | Quoted record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="topic-3.1.3.3-2"></a>

###### Part I and long-term extension (Part II)

> “Patients will initially be treated for 96 weeks with tiratricol, treatment effect will be evaluated after 96 weeks. After the 96 week treatment period, patients will enter Part II of the trial, evaluating long-term treatment.”

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

> “Part II of the study is a long-term extension with an additional 2 years of treatment and is currently on-going.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Registry inclusion criteria

> “The participant should be aged between 0 and 30 months on the day of inclusion.”
> “The participant should be male and have a pathogenic mutation in the MCT8 gene.”

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="topic-3.1.3.4-2"></a>

###### Registry exclusion criteria

> “Previous treatment with tiratricol.”
> “Previous treatment with LT4 and/or PTU and/or other anti-thyroid medication for a period longer than three months.”
> “Major illness or recent major surgery (within four weeks of baseline visit 1) unrelated to MCT8 deficiency.”
> “Patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose or galactose (the IMP contains lactose).”
> “Treatment with another investigational drug or participation in other interventional trial within three months prior to baseline visit 1.”

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Dose titration and target serum T3 range

> “The initial starting dose of tiratricol was 30-40 μg/kg/day (dose level 1).”
> “It was reasoned that tiratricol doses between 150 – 200 μg/kg/day would be a reasonable dose to administer in young children with MCT8 deficiency.”
> “Tiratricol was administered orally or through a feeding tube, with the dose divided into 1-3 administrations per day.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

> “The dose of tiratricol was escalated to target T3 at the lower limit of the normal range (LLN) down to 10% of the LLN, without dose limiting toxicities or side-effects.”
> “Patients were treated with a mean daily dose of 175 mcg/kg (compared to a mean dose in TRIAC trial I of 37 mcg/kg).”
> “A higher dose was applied with the aim to improve the severe neurocognitive phenotype of MCT8-deficiency.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.5-2"></a>

###### Treatment duration and exposure

> “Patients were initially treated for 96 weeks with tiratricol, and the treatment effect was evaluated after 96 weeks.”

Source: [Egetis Therapeutics Triac Trial II topline results announcement (2024)](https://www.egetis.com/news/egetis-announces-topline-results-of-the-phase-2-triac-trial-ii-with-emcitate-tiratricol-for-mct8-deficiency/)

> “Reflecting that only 1 patient discontinued the study, overall median exposure to tiratricol during Part I of the study was 97.1 weeks, range 2 to 107 weeks.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using GMFM-88 Total Score as a Co-primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Co-primary and secondary endpoints

> “The co-primary endpoints were GMFM-88 total score and BSID-III Gross Motor Skill Domain (age equivalent score) at week 96 compared to baseline and natural history scores from the TRIAC I study. T3 change from baseline was a secondary endpoint.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

> “Secondary outcomes included the effect of Triac on clinical and biochemical features related to thyrotoxicosis, and safety outcomes.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

<a id="topic-3.1.3.6.1-2"></a>

###### Registry description of the GMFM-88 and BSID-III co-primary measures

> “To evaluate the effects of tiratricol on neurodevelopment in young MCT8 deficiency patients, measured by the Gross Motor Function Measure (GMFM)-88 assessment. Potential result values range from 0 to 100%, the latter being representative for a 4-year old healthy child. A high score is equivalent to better/more neurodevelopment and is therefore a better outcome than a low score.”
> “To evaluate the effect of tiratricol treatment on neurodevelopment measured by the Bayley Scales of Infant Development (BSID-III) Gross Motor Skill Domain score. Potential total raw scores range from 0-72, and can be age-adjusted before analysis.”

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Enrolled and analyzed population

| Population | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

> “Of the 22 patients included in the ITT population, all were defined as having severe MCT8 deficiency, based on their genetic mutation.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

> “A total of 21 patients (median age 16 months at baseline) completed the 96-week treatment period.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Historical control comparison and post-hoc analyses

> “Primary outcomes were neurodevelopmental changes as measured by the Gross Motor Function Measure (GMFM)-88 and the Bayley Scales of Infant Development (BSID)-III gross motor domain, compared to untreated historical cohort patients aged 0-9 years. Post-hoc analyses focused on other neurodevelopmental domains.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

<a id="topic-3.1.3.7.2-2"></a>

###### Pre-specified historical control thresholds

> “Improvements versus the pre-specified historical control thresholds (GMFM-88: 9.8%= upper limit of the 95% CI from 0-9 years aged TRIAC-I patients; threshold in the BSID-III Gross Motor Skills Domain: 2.34 years) were clearly not shown.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Safety analysis set

> “Overall, 21 (95.5%) patients in the Safety Analysis Set (ITT population) reported 208 TEAEs in Part I of the study.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Screening, exclusion, discontinuation, and completion

> “Results: Between Dec 3, 2020, and Jun 22, 2022, we screened 23 male patients. One patient was excluded due to previous levothyroxine treatment and another discontinued treatment because of personal circumstances. A total of 21 patients (median age 16 months at baseline) completed the 96-week treatment period.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

> “One patient withdrew from the study for other reasons prior to reporting any TEAEs.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Age, disease severity, and time since diagnosis

> “Of the 22 patients included in the ITT population, all were defined as having severe MCT8 deficiency, based on their genetic mutation. Median age at time of enrolment was 16 months, range: 5 to 28 months, with most patients (63.6%) aged >12 months at baseline. The median time since diagnosis was 3 months, range 0 to 21 months.”
> “Two patients were younger than 6 months.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.8.2-2"></a>

###### Nutritional status, feeding, heart rate, and blood pressure

> “A large proportion of patients (54.5%) was under-weight at baseline.”
> “The majority of this young patient population had some difficulties with swallowing and choking, and there were 6 patients (27.3%) with a feeding tube at baseline.”
> “Two (9.5%) patients had resting heart rate (pulse rate) above the 90th percentile for the corresponding age, using cut-offs described in Fleming et al. 2011, and were defined as having tachycardia at baseline (compared with 40.9% of patients in TRIAC I).”
> “Thirteen (72.2%) patients had systolic hypertension at baseline based on definitions in Flynn et al. 2017 (compared with 34.3% in TRIAC I).”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Co-primary endpoints versus historical controls

| Co-primary endpoint | Mean difference versus untreated historical cohort after 96 weeks |
| --- | --- |
| GMFM-88 total score | “-2.42, 95%CI -4.36 to -0.48” |
| BSID-III gross motor domain | “0.21, 90%CI -0.19 to 0.61” |

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

> “Post-hoc analyses suggested small, significant, improvements in expressive language, fine motor, and cognition compared to untreated historical cohort patients.”
> “Conclusions: In this phase II, open-label, multicentre, clinical trial, we found no significant treatment effect of Triac on gross motor outcomes in young paediatric male patients with MCT8 deficiency.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

<a id="topic-3.1.3.8.3-2"></a>

###### Co-primary endpoints: change from baseline

> “In TRIAC II, very small numerical increases were observed at week 96 versus baseline on the primary endpoints reflecting neurodevelopment assessed by GMFM-88 total score (baseline mean 5.62%, week 96 mean 7.39%) and BSID-III Gross Motor Skills Domain (age equivalent score; baseline mean 2.0, week 96 mean 2.6).”
> “Overall, the observed small changes in the GMFM-88 total score and the BSID-III Gross Motor Skills Domain and other BSID-III domains (cognitive, receptive communication, expressive communication, and fine motor skills) may reflect the change in development that would have been observed without treatment.”
> “Overall, the CHMP concluded that the results of TRIAC-II did not support that tiratricol may beneficially influence the severe neurological phenotype of AHDS.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### Sponsor topline report

> “The numerical improvements versus baseline observed on the primary endpoints of neurocognitive development assessed by the GMFM-88 and BSID-III scales did not show a statistically significant improvement versus historical controls.”
> “Among key secondary endpoints, total serum thyroid hormone T3 concentrations were reduced significantly and durably in all patients, thereby verifying tiratricol’s ability to alleviate thyrotoxicosis in MCT8 deficiency patients.”

Source: [Egetis Therapeutics Triac Trial II topline results announcement (2024)](https://www.egetis.com/news/egetis-announces-topline-results-of-the-phase-2-triac-trial-ii-with-emcitate-tiratricol-for-mct8-deficiency/)

<a id="topic-3.1.3.8.3-4"></a>

###### Secondary endpoints: serum T3, body weight, blood pressure, and atrial ectopy

> “Mean serum T3 decreased by 3.24 nmol/L from 4.31 nmol/L at baseline to 1.07 nmol/L at week 96 (p<0.0001). From around week 12, serum T3 levels had reached a maximum reduction and did not decrease further with increasing dose of tiratricol.”
> “Following 96 weeks of treatment there was a 3.4 kg improvement in mean body weight (p<0.0001) that corresponded to a significant improvement in body weight for age MCT8 Z scores (1.129; p=0.0011), thus showing a somewhat larger than expected body weight increase from baseline compared to an untreated MCT8 deficiency population.”
> “Importantly, results on heart rate and systolic blood pressure in TRIAC II suggested higher-than-optimal dosing from a peripheral thyrotoxicosis perspective: there was an increase in SBP from 103.9 at baseline to 110.1 at week 96; DBP remained largely unchanged.”
> “In TRIAC II, the mean number of PACs per day was 19.2 at baseline.”
> “PAC rate was markedly reduced at Week 96 of TRIAC II, with a mean of 2.2 events per day.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Overview of treatment-emergent adverse events in Part I

| Event category | Participants, N=22, n (%) | Events |
| --- | --- | --- |
| Any treatment-emergent adverse event (TEAE) | “21 (95.5)” | “208” |
| Any TEAE at least possibly related to study treatment | “13 (59.1)” | “20” |
| Any TEAE leading to discontinuation of study treatment | “0” | “0” |
| Any TEAE of CTC Grade 3 or higher | “13 (59.1)” | “19” |
| Any serious treatment-emergent adverse event (SAE) | “10 (45.5)” | “26” |
| Any SAE at least possibly related to study treatment | “1 (4.5)” | “2” |
| Any SAE leading to death | “0” | “0” |

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.8.5-2"></a>

###### Treatment-related adverse events and serious adverse events

> “The most frequently reported TEAEs that were considered by the investigator to be at least possibly related to study treatment were in the gastrointestinal disorders MedDRA SOC, including diarrhoea reported by 3 (13.6%) patients.”
> “Nervous system disorders of seizure/partial seizures/dyskinesia were reported in 3 (13.6%) patients.”
> “Two treatment-related TEAEs of hypothyroidism were reported after tiratricol was abruptly withdrawn in 2 patients.”
> “Overall, these generally mild (CTCAE Grade 1) or moderate (CTCAE Grade 2) TEAEs resolved without any change in tiratricol dose.”
> “As previously observed in TRIAC trial I, the most frequently reported SAEs were in the MedDRA SOCs of infections and infestations (10 SAEs in 6 (27.3%)) patients, and nervous system disorders (4 SAEs in 3 (13.6%)) patients.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Heart rate and bone markers at the higher dose

> “However, with the high Emcitate mean dose in TRIAC II (175 µg/kg), the TH-like effects of Emcitate came into play so that a relevant reduction in mean HR was not observed (baseline 115 bpm, Week 96, 113.2 bpm).”
> “Thus, in TRIAC II, Emcitate tended to cause bone loss whereas in TRIAC I, there was a tendency to increased bone mass.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.8.5-4"></a>

###### Congress and sponsor reports of tolerability

> “No patients discontinued due to severe adverse events.”

Source: [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01)

> “The trial confirmed the well-tolerated safety profile seen in previous clinical studies, despite higher dosing per kg body weight compared to previous studies.”

Source: [Egetis Therapeutics Triac Trial II topline results announcement (2024)](https://www.egetis.com/news/egetis-announces-topline-results-of-the-phase-2-triac-trial-ii-with-emcitate-tiratricol-for-mct8-deficiency/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

Triac Trial II was a single-arm, open-label phase 2 trial that enrolled 22 participants aged 5 to 28 months (median 16 months), of whom 21 completed 96 weeks. Neurodevelopmental outcomes were compared with historical scores from untreated participants in Triac Trial I; the co-primary endpoints were not met (GMFM-88 mean difference -2.42; BSID-III gross motor mean difference 0.21). The absence of a concurrent control group limits the separation of treatment effect from expected development, and the post-hoc improvements in other domains were not pre-specified. Only two participants were younger than 6 months at baseline. The trial targeted serum T3 at or below the lower limit of normal with a mean dose of 175 mcg/kg, compared with 37 mcg/kg in Triac Trial I; the EMA assessment reported increases in systolic blood pressure and markers of bone loss at these doses, and the G-BA excluded the trial from the German benefit assessment because its titration targets differed from the product information. Serious adverse events occurred in 10 of 22 participants (45.5%). The results summarized here come from a regulatory assessment, a manufacturer topline report, a registry record, and a 2026 congress abstract.

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf); [van Geest et al. (2026)](https://www.endocrine-abstracts.org/ea/0119/ea0119ps1-02-01); [Egetis Therapeutics Triac Trial II topline results announcement (2024)](https://www.egetis.com/news/egetis-announces-topline-results-of-the-phase-2-triac-trial-ii-with-emcitate-tiratricol-for-mct8-deficiency/); [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf); [ClinicalTrials.gov NCT02396459](https://clinicaltrials.gov/study/NCT02396459)

<a id="topic-3.1.3.9-2"></a>

###### Regulatory appraisal: uncontrolled design, timing, and dose

> “It may be, that the window of opportunity had been closed in the majority of TRIAC-II patients; only two patients were below six months at baseline.”
> “The preliminary TRIAC II data did not show an effect of tiratricol on neurodevelopment, despite the inclusion of a younger patient population and the application of considerably higher tiratricol doses.”

Source: [European Medicines Agency Emcitate assessment report (2024)](https://www.ema.europa.eu/en/documents/assessment-report/emcitate-epar-public-assessment-report_en.pdf)

<a id="topic-3.1.3.9-3"></a>

###### German benefit assessment: dosing outside the product information

> “The data are unsuitable for the present benefit assessment since the specifications for the triiodothyronine (T3) target values for dose titration in this study deviate significantly from the requirements in the product information, thus higher maintenance doses being used.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 EMC Cohort Study

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Stated objective of the cohort study

> “Our previous trial showed improvement of key clinical and biochemical features during 1-year treatment with the T3 analogue Triac, but long-term follow-up data are needed.”
> “Also, it is relevant to determine whether the efficacy of a treatment demonstrated in a clinical trial (typically with a limited number of patients intrinsic to the low prevalence) is applicable in a real-life setting. Such long-term follow-up data of patients with MCT8 deficiency treated with Triac are currently lacking, particularly in young patients.”
> “In a joint international effort, we here retrospectively report long-term (up to 6 years) real-life follow-up data on children and adults with MCT8 deficiency treated with Triac.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study sites and observation dates

> “Between October 15, 2014, and January 1, 2020, 67 patients from 62 different families (with 46 different MCT8 mutations) had received Triac and were eligible for inclusion in this study.”
> “Patients were treated in 33 different sites in 18 countries: 19 sites were located in Europe, 4 in the Americas, 5 in Asia, 4 in Oceania and 1 in Africa (Supplementary Figure 2 (12)).”
> “Follow-up of the remaining patients continued to January 1, 2021.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Retrospective real-life cohort of off-label treatment

> “In this international pragmatic real-life cohort, data were collected retrospectively in patients with MCT8 deficiency, within our consortium of 33 hospitals in 18 countries, who have been treated with the T3 analogue Triac on an off-label use basis.”
> “The cohort consisted of (1) patients who finished the Triac Trial I protocol and continued on Triac treatment on an off-label use basis; and (2) additional patients who were identified after the recruitment phase of Triac Trial I or could not be enrolled in the Triac Trial I due to the absence of study sites in their country. For patients who had been enrolled in the Triac Trial I, data from the assessments at baseline and after 1 year of Triac treatment have been re-utilized and extended by novel long-term follow-up data.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.3-2"></a>

###### Consent and ethics review

> “The parents or guardians of all patients provided consent for off-label use of Triac to their caregiving physician. Under off-label use and with retrospective collection of data that are part of routine clinical care from medical files, no institutional board approval was needed in the majority (30) of hub centers.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Inclusion criteria

> “Eligible subjects were those with MCT8 deficiency (confirmed by the presence of a pathogenic mutation in the SLC16A2 gene), irrespective of age or comorbidities, who were treated with Triac on an off-label use basis following our previously established dose escalation protocol (11), and had their biochemical parameters measured in the central laboratory of the Erasmus MC, The Netherlands. This approach allowed for a uniform strategy of Triac dosing and monitoring of effects.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Washout, starting dose, and dose escalation

> “All patients discontinued antithyroid drugs, levothyroxine, or other thyroid hormone analogs (if applicable, eg, diiodothyropropionic acid [DITPA]) before treatment with Triac was initiated. After a washout period of 2 weeks, baseline measurements were recorded.”
> “The daily starting dose was based on body weight (175 µg Triac < 10 kg; 350 µg Triac ≥ 10 kg). The daily dose was increased with increments of 175 µg or 350 µg with a goal of attaining serum total T3 concentrations within the target range of 1.4 to 2.5 nmol/L. Guided by the exploratory neurodevelopmental outcomes in Triac Trial I (11), serum T3 concentrations < 1.4 nmol/L were allowed in children under 2.5 years of age in the absence of dose-limiting toxicities, leaving the possibility to administer higher Triac dosages, possibly increasing the potential for neurocognitive benefits.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.5-2"></a>

###### Time to maintenance dose and maintenance dose

> “The mean time to reach the maintenance dose was 5.0 (SD 4.7) months, with a mean of 2.7 (SD 1.1) dose increments. The median maintenance dose was 38 µg/kg/day (interquartile range, 31-61 µg/kg/day; range, 15-105 µg/kg/day).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.5-3"></a>

###### Treatment duration and exposure

> “The median treatment duration was 2.2 years (range, 0.2-6.2 years). Twelve (18%) of the 67 patients were treated for a period of more than 5 years and 26 (39%) of 67 patients were treated for a period of 2 to 5 years. The treatment exposure in this cohort was 180.4 patient years (Supplementary Figure 3B (12)).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Serum T3 Concentration as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary and secondary endpoints

> “The primary prespecified endpoint of this study was the change in serum T3 concentrations between baseline and last available measurement. The prespecified secondary endpoints were the change between baseline and last available body weight and body height (expressed as kg and cm, or weight-for-age and weight-for-height and height-for-age Z-scores, respectively, or as relative differences to the natural history reference; see Supplementary Methods (12)); heart rate (expressed as beats per minute, or heart-rate-for-age Z-score); serum thyroid-stimulating hormone (TSH; thyrotropin), free and total T4 concentrations; established biochemical markers that reflect thyroid hormone action in the liver (sex hormone-binding globulin [SHBG]), in the kidney (creatinine) and in muscle (creatine kinase [CK]); and Tanner stage of sexual maturation in patients who were aged between 8 and 18 years during treatment.”
> “The occurrence of (severe) adverse events related to Triac was actively monitored during treatment (see Supplementary Methods (12)).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.6.1-2"></a>

###### Rationale stated by the investigators: peripheral thyrotoxicosis

> “In MCT8-independent tissues, the elevated serum T3 concentrations cause chronic thyrotoxicosis with negative clinical sequelae that include being underweight and having cardiovascular dysfunction (8). Together, these disease characteristics result in substantial morbidity throughout life and predispose to high mortality in childhood (8).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.6.1-3"></a>

###### German benefit assessment: clinical relevance of serum T3

> “In the present therapeutic indication, the serum thyroid hormone T3 concentration is a clinically relevant laboratory parameter which is used for diagnosis and therapy management. Normalisation of serum values is an important therapeutic goal in peripheral thyrotoxicosis. No valid data could however be identified to show what effect a specific change in T3 concentration has on patient-individual symptomatology.”

Source: [G-BA justification to the resolution on tiratricol (2025)](https://www.g-ba.de/downloads/40-1465-11977/2025-10-16_AM-RL-XII_Tiratricol_D-1191_TrG_EN.pdf)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Analysis populations

> “All 67 participants received Triac and had at least 1 follow-up measurement of serum T3 concentrations and thus were included in the analysis of the primary endpoint. Of these 67 patients, 4 patients had not been treated longer than the mean time to optimal dose (5.0 months) and thus 63 participants were included in the analyses of the secondary endpoints. Of these 63 patients, 12 (19%) patients were treated for ≥ 5 years, 10 (16%) patients were treated for 3 to 5 years, 34 (53%) patients were treated for 1 to 3 years, and 7 (13%) patients were treated for < 1 year. Longitudinal within-subject analyses were performed in 38 patients with at least 2 years of follow-up.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Full analysis set and secondary-outcome set

> “Analysis on the primary outcome was based on the full analysis dataset, which included all patients who received at least 1 dose of Triac and who had at least 1 follow-up visit after the baseline assessment. Analyses on all prespecified secondary outcomes were done in all subjects who had a treatment duration that exceeded the mean time of dose escalation (defined as time from baseline measurement to the first follow-up visit on optimal dose), to ensure that treatment effects on secondary outcomes could be reliably assessed. Complementary analyses of secondary outcomes were performed on the full analysis dataset.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.7.2-2"></a>

###### Statistical methods

> “For all endpoints, P values and 95% CIs were calculated for the mean change between baseline and last available follow-up visit using paired t tests. Serum TSH and CK concentrations were first log-transformed to normalize the distribution. Complementary analyses after stratification by treatment duration (< 1 year, from 1 to 3 years, from 3 to 5 years and ≥ 5 years) were done using 1-way analysis of variance (ANOVA).”
> “In longitudinal within-subject analyses of the primary and secondary endpoints, performed in all subjects who were treated for at least 2 years, baseline data were compared with those obtained after 1 year (±4 months) of treatment and at the last available follow-up visit within the same subject, using repeated-measurement ANOVA.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.7.2-3"></a>

###### Missing data

> “Missing data can mainly be attributed to the poor clinical condition of patients (including restricted availability of serum); common manifestations of MCT8 deficiency, such as scoliosis and dystonic posturing that hamper investigations for which patients needed proper positioning; and patients receiving clinical care outside the designated hub centers. With the assumption that omission of data occurred randomly, and given the broad age range of the participants and small group size, pairwise deletion was used to adjust when the baseline data point was missing; for missing data that were captured throughout the treatment period, the last available measurement was used (if available).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.7.2-4"></a>

###### Historical natural-history comparison for growth outcomes

> “Deterioration of body weight and height with increasing age is part of the natural history of patients with MCT8 deficiency who are not treated with Triac (8). Therefore, the results of anthropometric parameters were expressed against the natural history of untreated patients.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Enrollment pathways and overlap with Triac Trial I

> “Among them, 27 patients had been enrolled in Triac Trial I and continued Triac treatment on an off-label use basis after completion of the trial protocol. Another 40 patients had been identified after the recruitment phase of Triac Trial I (n = 28) or could not be enrolled in the Triac Trial I due to the absence of study sites in their country (n = 12) (Supplementary Figure 1 (12)).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.1-2"></a>

###### Deaths and discontinuations during follow-up

> “During the study period, 3 patients died and 10 other patients discontinued Triac therapy (in 4 cases the parents decided to discontinue due to a lack of perceived benefit; 2 patients discontinued due to financial constraints or unavailability of Triac, and 4 patients discontinued for unknown reasons).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline age

> “At baseline, the median age was 4.6 years, with a range of 0.5 to 66 years. Of the 67 patients, 63 (94%) were younger than 18 years of age and 23 (34%) were younger than 2.5 years (Table 1 and Supplementary Figure 3A (12)).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.2-2"></a>

###### Baseline cohort characteristics

| Characteristic | Off-label use cohort, n = 67 |
| --- | --- |
| Age, median (range), years | “4.6 (0.5-66.8)” |
| Age 2.5 years or younger, n (%) | “23 (34%)” |
| Age older than 2.5 to 5 years, n (%) | “13 (19%)” |
| Age older than 5 to 10 years, n (%) | “17 (25%)” |
| Age older than 10 to 18 years, n (%) | “10 (15%)” |
| Age older than 18 years, n (%) | “4 (6%)” |
| Male, n (%) | “67 (100%)” |
| Continent of origin: Europe, n (%) | “45 (67%)” |
| Continent of origin: Asia, n (%) | “10 (15%)” |
| Continent of origin: Oceania, n (%) | “5 (7%)” |
| Continent of origin: North America, n (%) | “4 (6%)” |
| Continent of origin: South America, n (%) | “2 (3%)” |
| Continent of origin: Africa, n (%) | “1 (1%)” |
| Continuation after Triac Trial I, n (%) | “27 (40%)” |
| Direct off-label use, n (%) | “40 (60%)” |
| Serum T3, mean (SD), nmol/L | “4.58 (1.11)” |
| Body-weight-for-age Z-score, mean (SD) | “-2.80 (1.91)” |
| Tachycardia, n (%) | “21 (35%)” |

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

> “Body weight-for-age data were available for 66 patients.”
> “Heart rate data were available for 60 patients (denominator for percentage calculation).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Primary endpoint: serum T3 concentration at the last available visit

> “In the 67 patients assessed for the primary endpoint, mean serum T3 concentration decreased from 4.58 (SD 1.11) to 1.66 (SD 0.69) nmol/L (mean difference 2.92 nmol/L; 95% CI, 2.61-3.23 nmol/L; P < 0.0001; Fig. 1A and Table 2). Sixty (90%) of 67 patients reached T3 concentrations below 2.5 nmol/L, the upper limit of the target range.”
> “In patients who were treated for more than 2 years, serum T3 concentrations after 1 year of treatment and at the last visit did not significantly differ but were significantly reduced compared with baseline, indicating a sustained treatment effect (Fig. 1D and Supplementary Table 2 (12)).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.3-2"></a>

###### Changes from baseline to last visit in predefined outcomes

| Outcome | Baseline, mean (SD) | Last visit, mean (SD) | Mean change (95% CI) | P value |
| --- | --- | --- | --- | --- |
| T3, nmol/L (n = 67) | “4.58 (1.11)” | “1.66 (0.69)” | “−2.92 (−3.23 to −2.61)” | “<0.0001” |
| Weight-for-age Z-score (n = 58) | “−2.81 (1.94)” | “−2.64 (1.81)” | “0.17 (−0.18 to 0.53)” | “0.3263” |
| Weight-for-age Z-score minus predicted weight-for-age Z-score (n = 55) | “0.07 (1.83)” | “0.79 (1.92)” | “0.72 (0.36 to 1.09)” | “0.0002” |
| Height-for-age Z-score (n = 44) | “−1.84 (1.77)” | “−1.92 (1.51)” | “−0.09 (−0.50 to 0.32)” | “0.6705” |
| Height-for-age Z-score minus predicted height-for-age Z-score (n = 43) | “−0.44 (1.38)” | “0.14 (1.41)” | “0.58 (0.12 to 1.05)” | “0.0139” |
| Weight-for-height Z-score (n = 44) | “−2.02 (2.49)” | “−1.50 (2.44)” | “0.52 (−0.35 to 1.39)” | “0.2358” |
| Heart rate, bpm (n = 48) | “113 (21)” | “97 (20)” | “−17 (−24 to −10)” | “<0.0001” |
| Heart-rate-for-age Z-score (n = 48) | “1.59 (0.89)” | “0.96 (1.01)” | “−0.64 (− 0.98 to −0.29)” | “0.0005” |
| TSH, mU/L (n = 62) | “3.32 (2.30)” | “0.95 (0.73)” | “−2.38 (−2.98 to −1.77)” | “<0.0001” |
| Free T4, pmol/L (n = 64) | “9.5 (2.3)” | “3.4 (1.6)” | “−6.1 (−6.7 to −5.4)” | “<0.0001” |
| Total T4, nmol/L (n = 63) | “54.2 (11.8)” | “18.1 (9.8)” | “−36.1 (−39.5 to −32.7)” | “<0.0001” |
| Sex hormone-binding globulin, nmol/L (n = 48) | “245 (99)” | “209 (92)” | “−36 (−57 to −16)” | “0.0008” |
| Creatinine, µmol/L (n = 47) | “32 (11)” | “39 (13)” | “7 (6 to 9)” | “<0.0001” |
| Creatine kinase, U/L (n = 47) | “110 (87)” | “128 (80)” | “18 (−8 to 45)” | “0.2166” |

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.3-3"></a>

###### Body weight relative to the healthy reference population and to untreated historical controls

> “In the 63 patients analyzed for secondary endpoints, the mean body-weight-for-age Z-score increased, but not statistically significantly, from −2.81 SD (SD 1.94) at baseline to −2.64 SD (SD 1.81) at the last visit (mean difference 0.17 SD; 95% CI, −0.18 to 0.53; P = 0.3263), representing a mean increase of 5.7 kg (Table 2).”
> “The mean body weight-for-age Z-score at baseline was 0.07 SD-points above the natural history reference line and at last visit 0.79 SD-points above the natural history reference line, corresponding to a statistically significant mean increase of 0.72 SD-points (95% CI, 0.36-1.09; P = 0.0002, Table 2). Compared with the natural history of treatment-naïve patients with MCT8 deficiency, body weight-for-age improved (> 0.25 SD increase compared with the natural history reference) in 32 (57%) of 55 patients upon treatment and remained stable (−0.25 to 0.25 SD change compared with the natural history reference) in 11 (20%) of 55 patients (Fig. 1E).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.3-4"></a>

###### Body height

> “The mean body height-for-age increased from baseline to last visit by a mean of 15 cm, although the body height-for-age score did not significantly differ between baseline and last visit (mean difference −0.09 SD, 95% CI, −0.5 to 0.32; P = 0.6705) (Table 2). The mean body height-for-age Z-score at baseline was 0.44 SD-points under the natural history reference line and at last visit 0.14 SD-points above the natural history reference line, corresponding with a mean increase of 0.58 SD-points (95% CI, 0.12-1.05; P = 0.0139, Table 2).”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.3-5"></a>

###### Heart rate

> “Mean heart-rate-for-age Z-score decreased significantly (mean difference −0.64 SD; 95% CI, −0.98 to −0.29; P = 0.0005; Fig. 1G and Table 2), improving (> 0.25 SD decrease) in 29 (60%) of 48 patients and remaining stable (−0.25 to 0.25 SD change) in 10 (21%) of 48 patients. The proportion of patients with tachycardia (heart rate above the 90th percentile for the corresponding age, with cutoffs described by Fleming and colleagues (13)) decreased from 18 (38%) of 48 patients at baseline to 11 (23%) of 48 patients at the last visit.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.3-6"></a>

###### Thyroid function and tissue markers of thyroid hormone action

> “Mean serum TSH, free T4, and total T4 concentrations significantly declined upon Triac treatment (Table 2).”
> “Mean SHBG concentration, reflecting the liver-specific status of thyroid hormone action, decreased from 245 (SD 99) to 209 (SD 92) nmol/L (mean difference 36 nmol/L; 95% CI, 16-57; P = 0.0008) (Fig. 2A and Table 2).”
> “Creatinine, reflecting renal thyroid hormone activity, increased from 32 (SD 11) to 39 (SD 13) µmol/L (mean difference 7 µmol/L; 95% CI, 6-9; P < 0.0001) (Fig. 2C and Table 2).”
> “In contrast, CK, a marker of thyroid hormone activity in skeletal muscle, showed no statistically significant changes on Triac treatment [110 (SD 87) to 128 (SD 80) U/L; mean increase 18 U/L; 95% CI, −8 to 45; P = 0.2166; Fig. 2E and 2F and Table 2].”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.3-7"></a>

###### Sexual maturation

> “Available Tanner stage at the last visit of patients aged from 8 to 18 years during treatment showed delayed sexual maturation in 5 (29%) out of 17 patients (Supplementary Figure 7 (12)), similar to untreated patients with MCT8 deficiency (8). No effects of Triac treatment on sexual maturation were reported in these patients.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Adverse events and hospitalizations related to tiratricol

> “No severe adverse events related to Triac were reported during follow-up. Transient signs of increased thyrotoxicosis (increased irritability and anxiety, reduced sleep, increase in blood pressure, and tachycardia) were reported in a small subset of patients (5 of 67 patients; Supplementary Table 4). No hospitalizations related to Triac were reported.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.8.5-2"></a>

###### Deaths during follow-up

> “During the total treatment period, 3 patients died: a 13-year-old patient died due to sudden death, a 71-year-old patient died after aspiration and a 14-year-old patient died of unknown cause. This is in line with commonly observed causes of death in MCT8 deficiency, with cause of death also often being unknown (8). Postmortem examination was performed in none of the cases. At the time of death, all patients had been on a stable dose of Triac for > 1.5 years, > 4 years, and >2.5 years, respectively.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

This retrospective cohort included 67 participants treated off-label at 33 sites, of whom 27 (40%) had completed Triac Trial I; the baseline and 1-year data of those 27 participants are counted in both studies. Treatment duration ranged from 0.2 to 6.2 years, 4 participants were excluded from the secondary-outcome analyses, and missing measurements were handled by pairwise deletion and last available measurement. The change in body-weight-for-age Z-score relative to the healthy reference population was 0.17 SD (P = 0.3263), and the 0.72 SD increase was measured against a historical natural-history reference. The investigators state that the cohort may not represent all patients with MCT8 deficiency, that the real-life setting impeded optimal collection of efficacy and safety data, that care outside the designated centers could hamper adverse event reporting, and that neurodevelopmental outcomes were not collected uniformly. No concurrent comparator was included.

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="topic-3.1.4.9-2"></a>

###### Limitations stated by the investigators

> “This study has several limitations. First, it is unknown whether this cohort is fully representative for the entire population of patients with MCT8 deficiency. This cohort, however, represents a significant proportion of known patients (67 patients out of approximately 225 patients known in literature (8)). Second, this observational study collecting data on off-label use of Triac treatment in patients with MCT8 deficiency in a real-life treatment setting provides a less-controlled environment compared with a clinical trial, impeding optimal collection of efficacy and safety data. Patients have potentially also received care outside of their designated center, which could hamper reporting of adverse events.”
> “Third, this study precludes determining the optimal Triac dose for MCT8 deficiency for both the peripheral and neurocognitive phenotype as data on neurodevelopmental outcomes had not been uniformly collected.”

Source: [van Geest et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8852204/)

<a id="heading-3.1.5"></a>

#### 3.1.5 EMC Survival Study

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Survival objective

> “As thyrotoxicosis is linked to increased mortality, we investigated whether Triac treatment could improve survival in paediatric and adult male patients with MCT8 deficiency.”
> “We investigated the effects of Triac on all-cause mortality in patients with MCT8 deficiency.”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### International data collection

> “Genetic, clinical, biochemical and treatment data were collected from 173 sites in 48 countries through an international consortium on MCT8 deficiency, including patients that were in the Triac Trial I, a cohort of patients being part of the tiratricol managed access program, and published cases in the literature.”
> “Results from the study, will be presented as an oral presentation by Dr Floor van der Most on September 8, 2024, at the 46th Annual Meeting of the European Thyroid Association, in Athens, Greece.”

Source: [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Retrospective real-world cohort design

> “This retrospective international real-world cohort study investigated the effects of tiratricol on all-cause mortality in patients with MCT8 deficiency.”

Source: [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/)

<a id="topic-3.1.5.3-2"></a>

###### Sponsor analysis of the Erasmus University Medical Center cohort

> “The pre-NDA meeting was held on the back of the Breakthrough Therapy Designation granted in July 2025, based on FDA’s review of Egetis’ analysis of survival data from the international cohort study conducted by Erasmus University Medical Center (the EMC Survival Study).”

Source: [Egetis Therapeutics rolling NDA review announcement (2025)](https://www.egetis.com/news/egetis-granted-a-rolling-nda-review-by-fda-for-emcitate-tiratricol-based-on-currently-available-clinical-data/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Exclusion criteria and mutation classification

> “The impact of mutations on MCT8 transporter function was assessed in transfected cells and classified as mild, moderate or severe loss-of-function (LoF).”
> “Patients were excluded because (i) they were born before the disease’s discovery in 2004 (n=152), (ii) limited data (n=68) or (iii) unknown LoF (n=36).”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

No evidence found.

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using All-cause Mortality as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Mortality in MCT8 deficiency and the link to thyrotoxicosis

> “Mortality rates in MCT8 deficiency are high with 30% dying during childhood. The T3 analogue triiodothyroacetic acid (Triac) has been proven to safely alleviate peripheral thyrotoxicosis in patients with MCT8 deficiency. As thyrotoxicosis is linked to increased mortality, we investigated whether Triac treatment could improve survival in paediatric and adult male patients with MCT8 deficiency.”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Screened and included populations in the congress analysis

> “We screened 484 males with MCT8 deficiency of whom 228 were included.”
> “Baseline characteristics between Triac-treated (n=111) and untreated patients (n=117) were similar, except for untreated patients residing less often in Western countries (57 vs 78%).”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="topic-3.1.5.7.1-2"></a>

###### Study size reported in the New Drug Application

> “The Priority Review highlights the robust dataset we have in this rare genetic disease, with the NDA based on results from Triac Trial I (46 patients), Triac Trial II (22 patients), ReTRIACt (15 patients), EMC Cohort Study (67 patients), EMC Survival Study (>600 patients) and the U.S. Expanded Access Program (approximately 40 patients included in the NDA).”

Source: [Egetis Therapeutics first quarter 2026 interim report (2026)](https://www.egetis.com/news/interim-report-q1-2026/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Baseline comparisons, missing data, and survival models

> “Baseline characteristics, including age at symptom onset, age at diagnosis, country of residency, LoF, disease features, presence of a feeding tube, and prior treatment aiming to alleviate thyrotoxicosis were compared using Mann-Whitney U and Chi-Square test (5% level of significance).”
> “Missing data were imputed with multiple imputation prior to Kaplan-Meier, Log-rank, and Cox proportional-hazards models carried out to estimate the effect of Triac on survival.”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Screening, exclusion, and follow-up

> “We screened 484 males with MCT8 deficiency of whom 228 were included.”
> “Patients were excluded because (i) they were born before the disease’s discovery in 2004 (n=152), (ii) limited data (n=68) or (iii) unknown LoF (n=36).”
> “Median follow-up after diagnosis was 4.8 years [IQR=2.7–8.4] and we observed 32 deaths (5 treated vs 27 untreated).”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Comparison of treated and untreated participants

> “Baseline characteristics between Triac-treated (n=111) and untreated patients (n=117) were similar, except for untreated patients residing less often in Western countries (57 vs 78%).”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### All-cause mortality: congress analysis

> “Median follow-up after diagnosis was 4.8 years [IQR=2.7–8.4] and we observed 32 deaths (5 treated vs 27 untreated).”
> “No other baseline characteristics did significantly affect survival or the effect of Triac treatment.”
> “In this international real-world cohort study, we showed that Triac treatment in paediatric and adult patients with MCT8 deficiency was associated with a 3-times lower risk on mortality.”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="topic-3.1.5.8.3-2"></a>

###### All-cause mortality: hazard ratio

> “Tiratricol-treated patients had an approximately three times lower risk of all-cause mortality (Hazard Ratio= 0.28, 95% Confidence Interval= 0.09–0.91, p-value <0.05).”

Source: [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The congress analysis included 228 of 484 screened participants and compared 111 treated participants with 117 untreated participants; it reported 5 versus 27 deaths over a median follow-up of 4.8 years after diagnosis. Treatment was not randomized, and the treated and untreated groups differed in the proportion residing in Western countries (78% versus 57%). The reported hazard ratio (0.28, 95% CI 0.09 to 0.91) is an observational association; the authors state that confounding and immortal time bias remain potential threats to validity and that further analyses were ongoing. Missing data were handled by multiple imputation. Later manufacturer documents describe the EMC Survival Study as including more than 600 participants, while the only quoted estimate comes from the 228-participant congress analysis. As of the second-quarter 2026 interim report, the survival data had not yet been published in a peer-reviewed journal.

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0); [Egetis Therapeutics survival data announcement (2024)](https://www.egetis.com/news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/); [Egetis Therapeutics first quarter 2026 interim report (2026)](https://www.egetis.com/news/interim-report-q1-2026/); [Egetis Therapeutics second quarter 2026 interim report (2026)](https://www.egetis.com/news/egetis-interim-report-q2-2026/)

<a id="topic-3.1.5.9-2"></a>

###### Authors' statement on residual bias

> “To verify the robustness of our results, ongoing analyses aim to minimize confounding and immortal time bias, which pose potential threats to validity in cohort studies.”

Source: [van der Most et al. (2024)](https://distribute.m-anage.com/from.storage?image=awzvX5dvvcz083UIhJtlBGMn3B68-Zr00igiXeFHc5WfrjPT8distp0pTmW9zVdV0)

<a id="topic-3.1.5.9-3"></a>

###### Publication status of the survival data

> “In Italy and France, we plan to strengthen our value dossiers with survival data for Emcitate, once it has been published in a peer-reviewed journal by Erasmus Medical Center.”

Source: [Egetis Therapeutics second quarter 2026 interim report (2026)](https://www.egetis.com/news/egetis-interim-report-q2-2026/)

<a id="heading-3.1.6"></a>

#### 3.1.6 Pediatric TRIAC Case Series

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Stated objective

> “The objective of this study was to assess the clinical, imaging, biochemical, and genetic characteristics of patients with MCT8 deficiency treated with TRIAC, the doses used, and the response to treatment.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Institution and enrollment period

| Characteristic | Value |
| --- | --- |
| Institution | “Hospital de Pediatría S.A.M.I.C. Prof. Dr. Juan P. Garrahan, City of Buenos Aires, Argentina” |

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

> “During the period from January 2019 to November 2022, 4 patients from 4 different families were diagnosed with MCT8 deficiency and treated with triac at Hospital J. P. Garrahan.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Single-center case series

> “Here we report a case series of patients with MCT8 deficiency assessed at Hospital J. P. Garrahan and treated with TRIAC between January 2019 and December 2022.”
> “At the beginning of treatment and at the last control, age, weight and height progression, heart rate, blood pressure, feeding difficulty, neurological examination focused on neurodevelopment, and muscle tone and mass were assessed.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Genetic confirmation and consent

> “Molecular studies revealed pathogenic variants in all studied patients.”
> “The parents of all patients signed the informed consent for the use of TRIAC.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Dose and time to treatment initiation

> “The mean time from diagnosis to initiation of TRIAC was 2.7 months (±2.2 months).”
> “All patients received a daily intake, with a mean dose of 19 μg/kg (±6.8 SD).”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.5-2"></a>

###### Treatment start date and current daily dose by participant

| Participant | Start date | Current dose |
| --- | --- | --- |
| Participant 1 | “Nov-2019” | “22 μg/kg” |
| Participant 2 | “Jun-2020” | “18 μg/kg” |
| Participant 3 | “Jan-2022” | “10 μg/kg” |
| Participant 4 | “Jun-2022” | “26 μg/kg” |

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.5-3"></a>

###### Regulatory access in Argentina

> “In Argentina, the use of triac was approved by the National Drug, Food and Technology Administration of Argentina (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, ANMAT) in April 2015.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Serum T3 Concentration as a Biochemical Outcome

<a id="topic-3.1.6.6.1-1"></a>

###### Elevated T3 as the biochemical marker of MCT8 deficiency

> “Intrathyroidal T4 is low because it is rapidly converted to T3 which is elevated, this being the main biochemical marker.”
> “If it is clinically suspected, a complete thyroid profile should be requested because elevated T3 levels are a characteristic biochemical marker.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.6.1-2"></a>

###### Thyroid hormone assays

> “TSH, free T4, and total T3 were measured using the CMIA method on Abbott’s Architect i4000 Immunoassay Analyzer.”
> “Total T4 and SHBG were analyzed by chemiluminescence on the Immulite 2000 XPi system, and the reference intervals proposed by Elmlinger et al.8,9 were applied.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Included participants

| Population | Participants |
| --- | --- |
| Children treated with tiratricol | “4” |

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Follow-up and treatment duration by participant

| Participant | Follow-up duration | Treatment duration |
| --- | --- | --- |
| Participant 1 | “3 years and 6 months” | “32 months” |
| Participant 2 | “2 years and 6 months” | “22 months” |
| Participant 3 | “1 year and 1 month” | “6 months” |
| Participant 4 | “7 months” | “5 months” |

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Age, sex, and clinical presentation at diagnosis

> “All patients were male, with a median age at diagnosis of 1.38 years (range: 0.58–7.16).”
> “The most frequent clinical manifestations were axial hypotonia, spasticity, and overall developmental delay secondary to central hypothyroidism.”
> “Signs of peripheral hyperthyroidism were observed in 50% of patients; a lack of weight progression was the most frequent clinical manifestation.”
> “None had cardiovascular signs.”
> “In 2 patients, the MRI showed alterations in myelination.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.8.2-2"></a>

###### Thyroid function at diagnosis

> “Elevated T3 levels (3.19–4,7 ng/mL) were observed in 100% of patients.”
> “T4 and free T4 determinations were low in 3 patients and normal in 1 (receiving levothyroxine).”
> “All patients had elevated SHBG.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Biochemical response

> “T3 levels decreased in all patients, and even 3/4 reached normal values, over a mean time of 2.5 months.”
> “T4 and free T4 levels remained low in all cases and TSH levels were normal while receiving treatment.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.8.3-2"></a>

###### Total T3 at diagnosis and at the last control by participant

| Participant | Total T3 at diagnosis, ng/mL | Total T3 at last control, ng/mL |
| --- | --- | --- |
| Participant 1 | “3.3 (NV: 0.29–2.26)” | “2.7 (NV: 0.29–2.26)” |
| Participant 2 | “3.19 (NV: 1.03–2.3)” | “2.12 (NV: 1.03–2.3)” |
| Participant 3 | “4.7 (NV: 0.99–2.14)” | “1.52 (NV: 0.99–2.14)” |
| Participant 4 | “3.56 (NV: 0.29–2.26)” | “2.08 (NV: 0.29–2.26)” |

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.8.3-3"></a>

###### Clinical response

> “In our population, the main benefit was the improvement in spasticity, muscle tone, and developmental delay.”
> “The 2 children with malnutrition showed an improvement in weight.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Reported adverse reactions

> “No adverse reactions to TRIAC were reported during follow-up.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

The series included four participants from a single hospital and did not include a concurrent control group. Treatment duration ranged from 5 to 32 months. The authors describe retrospective data collection and unequal access to developmental stimulation therapies. The observed biochemical response and absence of reported adverse reactions in four participants cannot establish comparative effectiveness, quantify uncommon harms, or separate treatment effects on development from concomitant supportive care.

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="topic-3.1.6.9-2"></a>

###### Limitations stated by the authors

> “The limitations of this study are its retrospective nature and the limited number of patients, who were from different families with unequal access to stimulation therapies, which are a fundamental aspect in the progression of neurodevelopment.”

Source: [Gazek et al. (2023)](https://doi.org/10.5546/aap.2022-02968.eng)

<a id="heading-3.1.7"></a>

#### 3.1.7 Early TRIAC Intervention Case Report

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Stated aim of the case report

> “This case report describes a case of MCT8 deficiency treated with Triac, providing additional clinical evidence about the effect of Triac on peripheral as well as neurocognitive features, while neurodevelopment and myelination continued.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Institution

| Characteristic | Value |
| --- | --- |
| Institution | “Şanlıurfa Training and Research Hospital, Clinic of Pediatric Endocrinology, Şanlıurfa, Turkey” |

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Single-patient case report with scheduled assessments

> “The patient was assessed for clinical and biochemical signs of peripheral hyperthyroidism and neurodevelopmental changes, at baseline, 6 months and 12 months after start of treatment with Triac.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Referral and genetic diagnosis

> “A five-month-old boy was referred to the neurology clinic for feeding difficulty, hypotonia and developmental delay.”
> “Clinical exome sequencing conducted at 12 months for the etiologic investigation of the hypotonic infant revealed a de novo novel, hemizygous pathogenic variant (c.430+1G>C chrX: 73641903) in SLC16A2 and MCT8 deficiency was diagnosed”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Treatment initiation and dose titration

> “As soon as the diagnosis of MCT8 deficiency was confirmed and required local approvals were completed, Triac (Emcitate tablets, 350 mcg, Egetis Therapeutics, Klara Norra Kyrogata 26, Stockholm, Sweden) was started at 21 months via the compassionate use programme.”
> “After an initial dose of 175 mcg/day of Triac, fT3 dramatically decreased to 4.7 nmol/L (N=3.1-6.8) within two weeks.”
> “An individualized dose escalation of 175 mcg steps with a goal of attaining normal serum fT3 concentration was conducted using frequent clinic visits.”
> “After one year of treatment, fT3 concentration was reduced to 7.5 pmol/L (N=3.1-6.8), serum fT4 was 3.09 pmol/L (N=12-22) and daily dose of Triac was increased eventually to 1500 mcg/ day (133 mcg/kg/day) three times a day, po.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.5-2"></a>

###### Concomitant treatment

> “As dystonia remained prominent at six months of treatment, oral baclofen was started to ease pain and increase quality of life.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using BSID-III Composite Scores as a Neurodevelopmental Outcome

<a id="topic-3.1.7.6.1-1"></a>

###### Gap in neurodevelopmental evidence

> “However evaluation of neurocognitive outcome in Triac treated pediatric patients with MCT8 deficiency, especially before completion of brain development and myelination, are lacking”
> “Earlier clinical trials on the efficacy of Triac were not designed to detect neurodevelopmental outcomes and study populations’ age was very variable”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.6.1-2"></a>

###### Neurodevelopmental assessment method

> “Comprehensive developmental assessment was performed by a developmental-behavioral pediatrician.”
> “Detailed developmental history and a standardized assessment tool, Bayley Scales of Infant Development 3rd Edition (BSID-III) were used”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.6.1-3"></a>

###### Thyroid hormone assay

> “TH were measured using an immunoassay (Roche Modular E170 Immunology Analyzer, Hague Rd, Indianopolis, USA).”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Individual participant

> “The importance of this case is that it reports an in-depth clinical experience with an infant with MCT8 deficiency who was administered Triac.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Follow-up and adherence

> “Assessment of neurodevelopmental milestones and signs of hyperthyroidism were evaluated at baseline, 6 months and 12 months after treatment.”
> “After identifying adherence issues where there have been times where the patient did not receive treatment for 3-4 consecutive days, the patient was hospitalized for a short time-period and Triac dose adjustment was made.”
> “Problems with adherence to treatment were mainly linked to socioeconomic factors, as well as the populous family structure.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Clinical and biochemical findings at referral to endocrinology (19 months)

> “On physical examination, he was underweight (8.1 kg, -2.9 SDS) but his length was 80 cm (-1.3 SDS).”
> “Endocrine evaluation revealed normal TSH (2.83 mIU/mL), low fT4 (6.24 pmol/L N=12-22) and increased fT3 (15.65 pmol/L N=3.1-6.8) (Table 1) with an elevated T3/T4 ratio over 0.75.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.8.2-2"></a>

###### Neurodevelopmental status before treatment

> “At baseline, prior to Triac (21-months-old) developmental history revealed that developmental milestones were not achieved and BSID-III composite scores for cognitive [55; 95% confidence interval (CI): 51-67], language (47; 95% CI: 43-58) and motor (46; 95% CI: 43-58) evaluation were below two SDS for age.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Neurodevelopmental outcomes at 6 and 12 months

> “At six months of Triac treatment, BSID-III composite scores remained below two SDS for age but he started to habituate to objects, recognize and smile at his mother, respond to a person’s voice by turning his head, raise his face while in prone position and hold his head steady for a few seconds while in sitting position.”
> “At 12 months, BSID-III composite scores remained unchanged (below two SDS for age), but he started to respond to his name by turning his head, follow a person across the room with eyes and head, and hold his head steady for at least 15 seconds and dystonia was improved.”
> “Regression was not observed in any developmental domain.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.8.3-2"></a>

###### Peripheral thyrotoxicosis outcomes

> “By seven months of treatment, the goal of attaining normal serum fT3 was achieved continuously.”
> “Without change in caloric consumption per kilograms, body weight for length SDS have improved significantly at six months of treatment which was sustained until 12 months afte start of Triac.”
> “Systolic and diastolic blood pressure was decreased and stabilized by 12 months of Triac treatment (Table 1).”
> “Mild elevation in ALT, AST and CK improved within six months”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.8.3-3"></a>

###### Clinical and biochemical measures at baseline and after 12 months of treatment

| Measure | Baseline (21 months of age) | 12 months after treatment start |
| --- | --- | --- |
| Weight SDS | “-2.9” | “-1.8” |
| Resting heart rate, bpm (percentile) | “150 (90th-99th)” | “95 (25th)” |
| TSH, mIU/mL | “0.8” | “0.7” |
| Free T3, pmol/L | “11.7” | “7.5” |

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.8.3-4"></a>

###### Free T3 immunoassay interference during treatment

> “Despite precise treatment, extremely high fT3 (45.1 and 39 pmol/L at the sixth and ninth months of treatment, respectively) were observerd.”
> “This unexpected, drastic increase was presumed to be explained by molecular interference of Triac and fT3 in the biochemical analysis, and Triac dose was not changed.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Drug-related adverse effects

> “No drug related toxicity, need for dose reduction or adverse effect was encountered.”
> “He developed upper respiratory tract infection three times during this period which was not attributed to Triac, since they resolved while drug was continued.”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

This is one participant followed without a comparator. BSID-III composite scores remained below two SDS for age at 6 and 12 months despite attainment of individual developmental milestones. The report also describes adherence interruptions of 3 to 4 consecutive days, suspected free T3 immunoassay interference, and oral baclofen introduced at 6 months. These factors limit attribution of changes to tiratricol. The maintenance dose (1,500 mcg/day, 133 mcg/kg/day) was higher than doses previously described, and a single participant provides no estimate of adverse-event frequency.

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="topic-3.1.7.9-2"></a>

###### Limitations stated by the authors

> “Although an improvement in developmental composite scores during follow-up assessments were not observed, an improvement in critical developmental milestones were present.”
> “It may have taken longer in the current patient due to poor adherence, especially in the first months of treatment.”
> “The Triac dose (136 mcg/ kg/day) required to normalize fT3 was much higher in the present case than previously described (23-48 mcg/kg/day)”

Source: [Ünsal and Hayran (2024)](https://jcrpe.org/pdf/cf9d60d6-523c-458a-a2e6-78728d3ffbb0/articles/jcrpe.galenos.2023.2023-10-1/JCRPE-16-116-En.pdf)

<a id="heading-3.1.8"></a>

#### 3.1.8 Real-world Tiratricol Case Report

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

Additional sources: [Pribilincová et al. (2025b)](https://www.sciencedirect.com/science/article/pii/S2214624525000218)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Institutions

| Characteristic | Value |
| --- | --- |
| Pediatric endocrinology | “Comenius University Medical Faculty, National Institute of Children´s diseases, Pediatric Endocrine Unit, Bratislava, Slovakia” |
| Pediatric neurology | “Comenius University Medical Faculty, National Institute of Children´s Diseases, Pediatric neurology, Bratislava, Slovakia” |

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Single-patient case report

> “We report a patient, who was born from an uneventful pregnancy in the 37th week of gestation, Apgar score 8/9, eutrophic.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

Additional sources: [Pribilincová et al. (2025b)](https://www.sciencedirect.com/science/article/pii/S2214624525000218)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Clinical course and genetic diagnosis

> “Neurological follow up showed deterioration of axial muscle tone around 5 months, but till 8 months there was evident regression in psychomotor development, pronounced hypotonia.”
> “At 23 months NGS revealed mutation in SLC16A2 gene (c.940C T (p.Arg314Ter): Allan-Herndon-Dudley syndrome i.e. MCT8 deficiency.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Tiratricol initiation and dose adjustment

> “We started treatment with Tiratricol 350 ug daily, increasing the dose during 6 weeks to 75mg/kg daily, when the boy started to gain weight, slightly improved the axial muscle tone.”
> “The dose was lowered and has been kept till now with normalised fT3.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="topic-3.1.8.5-2"></a>

###### Prior levothyroxine treatment

> “Endocrine assessment at 8 months was appropriate, but at 13 months showed signs of primary hypothyroidism and Thyroxin was started.”
> “After 5 months on medication there was no change.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Clinical Response as an Outcome Measure

No evidence found.

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Individual participant

> “We report a patient, who was born from an uneventful pregnancy in the 37th week of gestation, Apgar score 8/9, eutrophic.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Thyroid function before tiratricol (32 months of age)

| Measure | Value |
| --- | --- |
| TSH | “4,52 mU/l” |
| Free T4 | “6,61 pmol/l” |
| Free T3 | “14,72 pmol/l” |

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="topic-3.1.8.8.2-2"></a>

###### Growth and imaging before tiratricol

> “Vomiting led to elimination diet, which helped but he didn´t gain weight, while growing normally.”
> “At 13 months MRI: delayed white matter myelinisation.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Clinical and biochemical course during treatment

> “The dose was lowered and has been kept till now with normalised fT3.”
> “He is improving now his psychomotor development, slowly gaining weight on 5O mg/kg of Tiratricol.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

Additional sources: [Pribilincová et al. (2025b)](https://www.sciencedirect.com/science/article/pii/S2214624525000218)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Events during dose escalation

> “But in another 8 weeks, he started vomit, was constipated, lost weight.”
> “At this time TSH was supressed.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

The evidence for this case is one participant described in a congress abstract without a comparator. The abstract gives the starting dose in micrograms per day and later doses in mg/kg per day, so the dose units cannot be confirmed from the abstract. Epileptic encephalopathy and antiepileptic treatment during follow-up limit attribution of psychomotor changes to tiratricol. The full case report could not be retrieved for this review.

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="topic-3.1.8.9-2"></a>

###### Concurrent neurological treatment

> “Evidence of epileptic encephalopathy on EEG and seizures led to antiepileptic treatment with good response.”

Source: [Pribilincová et al. (2025a)](https://www.endocrine-abstracts.org/ea/0110/ea0110P1209)

<a id="heading-3.1.9"></a>

#### 3.1.9 Bioavailability/Bioequivalence Study

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Primary and secondary objectives

> “This study investigates the pharmacokinetics (PK) of tiratricol.”
> “The primary objective was to establish bioequivalence between 350μg tiratricol oblong tablets and 350μg tiratricol round tablets.”
> “The secondary objectives were to estimate the effect of food by comparing both 175μg and 1050μg tiratricol oblong tablet doses in fasted versus fed states, and to assess dose-proportionality of tiratricol oblong tablets in a fasted state.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="topic-3.1.9.1-2"></a>

###### Registered primary objective

> “To establish bioequivalence between 350 μg Emcitate oblong tablets and 350 μg Emcitate round tablets in a fasted state (both administered as single oral doses of 1 × 350 μg tablet dispersed in water).”
> “To provide further information on the safety and tolerability of Emcitate oblong tablets and Emcitate round tablets following oral administration.”

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Study site, sponsor, and enrollment dates

| Characteristic | Value |
| --- | --- |
| Study participating centre | “Quotient Sciences Limited” |
| Country of recruitment | “United Kingdom” |
| Sponsor | “Rare Thyroid Therapeutics International AB” |
| Protocol serial number | “Sponsor code MCT8-2023-5” |
| Date of first enrolment | “06/07/2023” |
| Date of final enrolment | “31/08/2023” |

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Randomized five-period crossover design

> “This novel Phase 1, randomized, five-period cross-over study was a hybrid combination of a two-period cross-over and a three-period balanced incomplete block design in healthy adult male subjects (n = 30) with a washout of ≥3 days between periods.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Key inclusion criteria

| Criterion | Registered text |
| --- | --- |
| Age | “Aged 18 to 55 years inclusive at the time of signing informed consent” |
| Sex and health status | “Healthy males” |
| Body mass index | “Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening” |
| Body weight | “Weight 50 to 100 kg at screening” |

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="topic-3.1.9.4-2"></a>

###### Selected exclusion criteria

> “Values outside the normal reference range for any of the following safety laboratory analytes: serum TSH, T3, T4, FT4, total cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, ferritin, parathyroid hormone (PTH) or sex hormone binding globulin (SHBG,) if judged by the investigator to be clinically significant at the screening visit”
> “Current smokers and those who have smoked within the last 12 months”

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Single-dose administration

> “Single oral doses of tiratricol were administered (see table).”
> “All subjects received the treatments for the critical assessment of bioequivalence and 3 additional ones.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="topic-3.1.9.5-2"></a>

###### Registered treatments

| Treatment | Registered description |
| --- | --- |
| A | “350 μg Emicate® (Tiratricol) round tablet, fasted” |
| B | “350 μg Emicate® (Tiratricol) oblong tablet, fasted” |
| C | “1050 μg Emicate® (Tiratricol) oblong tablet, fasted” |
| D | “1050 μg Emicate® (Tiratricol) oblong tablet, fed” |
| E | “175 μg Emicate® (Tiratricol) oblong tablet, fasted” |
| F | “175 μg Emicate® (Tiratricol) oblong tablet, fed” |

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using AUC and Maximum Serum Concentration as the Bioequivalence Endpoints

<a id="topic-3.1.9.6.1-1"></a>

###### Registered primary outcome measure

> “PK parameters Cmax, AUC(0-last) and AUC(0-inf) for tiratricol in serum measured using blood samples at pre-dose and multiple timepoints up to 72 h post-dose”

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="topic-3.1.9.6.1-2"></a>

###### Other assessments

> “Serum tiratricol, standard PK parameters, and safety were assessed.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Planned and enrolled participants

| Population | Participants |
| --- | --- |
| Target sample size at registration | “45” |
| Total final enrolment | “30” |

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

###### Safety and pharmacokinetic analysis counts by treatment

| Treatment | Safety analysis | Pharmacokinetic analysis |
| --- | --- | --- |
| A: round tablet, 350 micrograms, fasted | “29” | “29” |
| B: oblong tablet, 350 micrograms, fasted | “29” | “28” |
| C: oblong tablet, 1,050 micrograms, fasted | “24” | “24” |
| D: oblong tablet, 1,050 micrograms, fed | “20” | “20” |
| E: oblong tablet, 175 micrograms, fasted | “25” | “25” |
| F: oblong tablet, 175 micrograms, fed | “20” | “20” |

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Bioequivalence of oblong and round tablets

> “Bioequivalence was established between 350μg tiratricol oblong and 350μg tiratricol round tablets in terms of AUC and Cmax with a serum half-life of approximately 13h for both administrations.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="topic-3.1.9.8.3-2"></a>

###### Food effect

> “Overall exposure (AUC) was comparable between the fasted and fed state.”
> “Absorption was rapid in the fasted state (median Tmax 0.5 hr) but slower in the fed state (median Tmax approximately 1.5 hr), with Cmax 67–70% lower.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="topic-3.1.9.8.3-3"></a>

###### Dose proportionality

> “Cmax following treatment with the 175μg, 350μg, and 1050μg oblong tablet doses increased proportionally with increasing dose, whereas AUC increased in a slightly greater than proportional manner with increasing dose.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Tolerability and serious adverse events

> “Tiratricol was well tolerated in all doses and fasting states, with no serious adverse events recorded.”

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

This single-dose crossover study enrolled 30 healthy adult male participants aged 18 to 55 years. Its results address formulation comparability, food effects, and dose proportionality. Analysis counts ranged from 20 to 29 participants per treatment, and the congress abstract does not report participant disposition, baseline demographics, adverse-event counts, or confidence intervals for the bioequivalence comparison. The registry record states that participant-level data will not be shared. Single-dose exposure in adults provides limited information on safety during lifelong treatment in children.

Source: [Sonesson et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc12.6); [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

<a id="topic-3.1.9.9-2"></a>

###### Data availability

> “The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.”

Source: [ISRCTN ISRCTN98332431](https://www.isrctn.com/ISRCTN98332431)

## Related pages
- [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations.md)
- [Emcitate (tiratricol): MCT8 deficiency](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/executive-summary.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Product information and disease description](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description.md)
- [Emcitate (tiratricol) in MCT8 deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economics.md)
- [Emcitate (tiratricol) in MCT8 deficiency: References](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/references) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/references.md)
- [Emcitate (tiratricol) in MCT8 deficiency: new drug review](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review.md)
- [Emcitate (tiratricol) in MCT8 deficiency: prevalence by geography](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/prevalence.md)
- [Emcitate (tiratricol) in MCT8 deficiency: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/emcitate--mct8-deficiency/cost-effectiveness-analyses.md)
